US20240033266A1 - Combination therapy involving diaryl macrocyclic compounds - Google Patents
Combination therapy involving diaryl macrocyclic compounds Download PDFInfo
- Publication number
- US20240033266A1 US20240033266A1 US18/138,644 US202318138644A US2024033266A1 US 20240033266 A1 US20240033266 A1 US 20240033266A1 US 202318138644 A US202318138644 A US 202318138644A US 2024033266 A1 US2024033266 A1 US 2024033266A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- cancer
- compound
- kras
- inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 diaryl macrocyclic compounds Chemical class 0.000 title claims abstract description 78
- 238000002648 combination therapy Methods 0.000 title description 2
- 102200006538 rs121913530 Human genes 0.000 claims abstract description 272
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 160
- 238000000034 method Methods 0.000 claims abstract description 99
- 201000011510 cancer Diseases 0.000 claims abstract description 96
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 203
- 150000001875 compounds Chemical class 0.000 claims description 202
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 claims description 171
- 238000011282 treatment Methods 0.000 claims description 146
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 123
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 123
- 150000003839 salts Chemical class 0.000 claims description 65
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 64
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 64
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 claims description 63
- 229940124988 adagrasib Drugs 0.000 claims description 61
- 206010009944 Colon cancer Diseases 0.000 claims description 41
- 241001465754 Metazoa Species 0.000 claims description 34
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 claims description 30
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 30
- 239000003124 biologic agent Substances 0.000 claims description 30
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 30
- 201000002528 pancreatic cancer Diseases 0.000 claims description 30
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 30
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 29
- 102000004889 Interleukin-6 Human genes 0.000 claims description 25
- 108090001005 Interleukin-6 Proteins 0.000 claims description 25
- 150000003384 small molecules Chemical class 0.000 claims description 23
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 20
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 20
- 201000002510 thyroid cancer Diseases 0.000 claims description 20
- 206010014733 Endometrial cancer Diseases 0.000 claims description 19
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 19
- 229940127089 cytotoxic agent Drugs 0.000 claims description 19
- 230000001394 metastastic effect Effects 0.000 claims description 19
- 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 claims description 18
- 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 claims description 18
- 206010060862 Prostate cancer Diseases 0.000 claims description 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 18
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 18
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 18
- 206010017758 gastric cancer Diseases 0.000 claims description 18
- 208000005017 glioblastoma Diseases 0.000 claims description 18
- 238000009169 immunotherapy Methods 0.000 claims description 18
- 201000011549 stomach cancer Diseases 0.000 claims description 18
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 17
- 230000028327 secretion Effects 0.000 claims description 17
- 206010046766 uterine cancer Diseases 0.000 claims description 17
- 108091034117 Oligonucleotide Proteins 0.000 claims description 12
- 108020004459 Small interfering RNA Proteins 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 229920002477 rna polymer Polymers 0.000 claims description 12
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 11
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- YRYQLVCTQFBRLD-UIOOFZCWSA-N 2-[(2S)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile Chemical compound C(C=C)(=O)N1[C@H](CN(CC1)C=1C2=C(N=C(N=1)OC[C@H]1N(CCC1)C)CN(CC2)C1=CC=CC2=CC=CC(=C12)C)CC#N YRYQLVCTQFBRLD-UIOOFZCWSA-N 0.000 claims description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 10
- 210000004072 lung Anatomy 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 201000003708 skin melanoma Diseases 0.000 claims description 10
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 claims description 9
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 9
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 claims description 9
- 201000003076 Angiosarcoma Diseases 0.000 claims description 9
- 206010003571 Astrocytoma Diseases 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 206010005949 Bone cancer Diseases 0.000 claims description 9
- 208000018084 Bone neoplasm Diseases 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 201000009030 Carcinoma Diseases 0.000 claims description 9
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 9
- 206010065859 Congenital fibrosarcoma Diseases 0.000 claims description 9
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 9
- 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 claims description 9
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 9
- 208000032612 Glial tumor Diseases 0.000 claims description 9
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 9
- 206010018338 Glioma Diseases 0.000 claims description 9
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 9
- 208000017604 Hodgkin disease Diseases 0.000 claims description 9
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 9
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 9
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 9
- 206010070665 Mesoblastic nephroma Diseases 0.000 claims description 9
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 9
- 206010029260 Neuroblastoma Diseases 0.000 claims description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 9
- 206010038389 Renal cancer Diseases 0.000 claims description 9
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 9
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 9
- 206010057644 Testis cancer Diseases 0.000 claims description 9
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 9
- 201000007983 brain glioma Diseases 0.000 claims description 9
- 210000000481 breast Anatomy 0.000 claims description 9
- 201000007452 breast secretory carcinoma Diseases 0.000 claims description 9
- 201000010881 cervical cancer Diseases 0.000 claims description 9
- 201000010180 childhood kidney cell carcinoma Diseases 0.000 claims description 9
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 9
- 201000008168 congenital mesoblastic nephroma Diseases 0.000 claims description 9
- 201000004101 esophageal cancer Diseases 0.000 claims description 9
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 9
- 201000010982 kidney cancer Diseases 0.000 claims description 9
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 9
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 9
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 claims description 9
- 206010038038 rectal cancer Diseases 0.000 claims description 9
- 201000001275 rectum cancer Diseases 0.000 claims description 9
- 201000000849 skin cancer Diseases 0.000 claims description 9
- 201000003120 testicular cancer Diseases 0.000 claims description 9
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 9
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 206010068116 Metastatic uterine cancer Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 8
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 abstract description 111
- 229940124785 KRAS inhibitor Drugs 0.000 abstract description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 592
- 229940125904 compound 1 Drugs 0.000 description 199
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 135
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 135
- 102000001332 SRC Human genes 0.000 description 122
- 108060006706 SRC Proteins 0.000 description 122
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 112
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 103
- 210000004027 cell Anatomy 0.000 description 92
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 81
- 229910052805 deuterium Inorganic materials 0.000 description 81
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 77
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 76
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 76
- 125000004093 cyano group Chemical group *C#N 0.000 description 57
- 229910052736 halogen Inorganic materials 0.000 description 55
- 150000002367 halogens Chemical group 0.000 description 55
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 50
- 125000001072 heteroaryl group Chemical group 0.000 description 44
- 230000002195 synergetic effect Effects 0.000 description 44
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 37
- 239000003814 drug Substances 0.000 description 37
- 230000035772 mutation Effects 0.000 description 33
- 102100030708 GTPase KRas Human genes 0.000 description 32
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 28
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 23
- 229940100601 interleukin-6 Drugs 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 125000002950 monocyclic group Chemical group 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 14
- 210000004881 tumor cell Anatomy 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 13
- 108090000397 Caspase 3 Proteins 0.000 description 12
- 102100029855 Caspase-3 Human genes 0.000 description 12
- 230000037396 body weight Effects 0.000 description 12
- 102000047934 Caspase-3/7 Human genes 0.000 description 11
- 108700037887 Caspase-3/7 Proteins 0.000 description 11
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 11
- 229960002949 fluorouracil Drugs 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 108091008611 Protein Kinase B Proteins 0.000 description 10
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 10
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 10
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 10
- 238000011284 combination treatment Methods 0.000 description 10
- 229960004768 irinotecan Drugs 0.000 description 10
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 9
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 9
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 9
- 125000001246 bromo group Chemical group Br* 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 125000001153 fluoro group Chemical group F* 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 9
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 101710113436 GTPase KRas Proteins 0.000 description 8
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 229960000397 bevacizumab Drugs 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 8
- 235000008191 folinic acid Nutrition 0.000 description 8
- 239000011672 folinic acid Substances 0.000 description 8
- 229960001691 leucovorin Drugs 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 7
- 229960001756 oxaliplatin Drugs 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 6
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 6
- 102000016914 ras Proteins Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
- 229960004562 carboplatin Drugs 0.000 description 5
- 230000005754 cellular signaling Effects 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000006882 induction of apoptosis Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 206010069755 K-ras gene mutation Diseases 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100036154 Platelet basic protein Human genes 0.000 description 4
- 101150040459 RAS gene Proteins 0.000 description 4
- 101150076031 RAS1 gene Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 4
- 229940028652 abraxane Drugs 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 229960004117 capecitabine Drugs 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 229940125399 kras g12c inhibitor Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960001972 panitumumab Drugs 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 3
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 3
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102100040557 Osteopontin Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000012083 RIPA buffer Substances 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 229940122924 Src inhibitor Drugs 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 125000003636 chemical group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 3
- 229960003301 nivolumab Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000011885 synergistic combination Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- DGHHQBMTXTWTJV-BQAIUKQQSA-N 119413-54-6 Chemical compound Cl.C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 DGHHQBMTXTWTJV-BQAIUKQQSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 2
- 102100023701 C-C motif chemokine 18 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 2
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 229940124783 FAK inhibitor Drugs 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 2
- 101000978371 Homo sapiens C-C motif chemokine 18 Proteins 0.000 description 2
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 2
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 description 2
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 2
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 102000004369 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 2
- 108090000969 Insulin-like growth factor-binding protein 4 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010081689 Osteopontin Proteins 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 125000005110 aryl thio group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229950003054 binimetinib Drugs 0.000 description 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 230000001447 compensatory effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229950001969 encorafenib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 102000052611 human IL6 Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000022632 negative regulation of interleukin-6 secretion Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229960002633 ramucirumab Drugs 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008261 resistance mechanism Effects 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000005737 synergistic response Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960002760 ziv-aflibercept Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical class OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical class OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 102100040768 60S ribosomal protein L32 Human genes 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010027164 Amanitins Proteins 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 102100034278 Annexin A6 Human genes 0.000 description 1
- 108090000656 Annexin A6 Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 108010083700 Chemokine CCL20 Proteins 0.000 description 1
- 108010083647 Chemokine CCL24 Proteins 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 102000005417 Crk Associated Substrate Protein Human genes 0.000 description 1
- 108010031504 Crk Associated Substrate Protein Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 102100020997 Fractalkine Human genes 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 101150012162 H-RAS gene Proteins 0.000 description 1
- 101000672453 Homo sapiens 60S ribosomal protein L32 Proteins 0.000 description 1
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000871017 Homo sapiens Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000734676 Homo sapiens Inactive tyrosine-protein kinase PEAK1 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102100034687 Inactive tyrosine-protein kinase PEAK1 Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100026019 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028561 Myeloid metaplasia Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 101150062285 PGF gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000018546 Paxillin Human genes 0.000 description 1
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- RUDNHCHNENLLKM-UHFFFAOYSA-N ac1mj1v6 Chemical compound O=C1NC(CC(O)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CSC1=C2C2=CC=C(O)C=C2N1 RUDNHCHNENLLKM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- KMGARVOVYXNAOF-UHFFFAOYSA-N benzpiperylone Chemical compound C1CN(C)CCC1N1C(=O)C(CC=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 KMGARVOVYXNAOF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical class OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 208000026535 luminal A breast carcinoma Diseases 0.000 description 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 150000002678 macrocyclic compounds Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 230000006510 metastatic growth Effects 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000004650 oncogenic pathway Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000008008 oral excipient Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000003566 phosphorylation assay Methods 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- FIKPXCOQUIZNHB-WDEREUQCSA-N repotrectinib Chemical compound C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005738 synergistic apoptotic response Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000001962 taste-modifying agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 208000036907 triple-positive breast carcinoma Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
- Kirsten Rat Sarcoma Viral Oncogene homolog KRAS is one of three RAS protein family members (N, H, and K-RAS) that are small membrane bound intracellular GTPase proteins. KRAS cycles between an inactive guanosine diphosphate (GDP)-bound state and an active guanosine triphosphate (GTP)-bound state. Active GTP-bound KRAS interacts with numerous effectors to stimulate multiple signaling pathways (e.g. PI3K-AKT-MTOR, RAF-MEK-ERK) to affect a range of cellular processes (e.g. survival, proliferation, cytoskeletal organization).
- GDP inactive guanosine diphosphate
- GTP active guanosine triphosphate
- Active GTP-bound KRAS interacts with numerous effectors to stimulate multiple signaling pathways (e.g. PI3K-AKT-MTOR, RAF-MEK-ERK) to affect a range of cellular processes (e.g. survival, proliferation
- KRAS is one of the most frequently mutated oncogenes across a broad spectrum of human cancers (18%, Catalogue of Somatic Mutations in Cancer (COSMIC) database v90), including non-small cell lung, colorectal, pancreatic, uterine, bladder, stomach, renal, breast, skin, prostate, acute myeloid leukemia, cervical, liver acute lymphoblastic leukemia, ovarian, and brain cancers.
- KRAS mutations primarily occur in KRAS codons 12 and 13, and also occur in codons 18, 61, 117, and 146 at low frequencies and have distinct effects on tumor cell signaling based on the codon and missense mutation (Stolze et al. Sci Rep. 2015; 5:8535).
- KRAS G12C inhibitor MRTX849 demonstrated tumor regression in only 17 of 26 (65%) of KRAS G12C-positive cell line- and patient-derived mouse xenograft models from multiple tumor types and multiple resistance mechanisms including KRAS nucleotide cycling and feedback reactivation and/or bypass KRAS dependence limit the efficacy and duration of response of MRTX849 in non-clinical models (Hallin et al, Cancer Discovery, 2020, 10(1), 54-71).
- Covalent inhibitors of KRAS G12C have been reported to be more effective when combined with immune checkpoint inhibitory monoclonal antibodies such as those that block the programmed death-1 (PD-1) (Canon et al, Nature, 2019, 575, 217-223). Combinations that target MAPK pathway feedback re-activation, RTK-induced PI3K pathway activation, increased apoptosis, and suppress the proinflammatory tumor microenvironment will be necessary to provide significant improvements in clinical benefit.
- PD-1 programmed death-1
- Tumor cells reprogram the tumor microenvironment by many processes (e.g. immune suppression, induction of angiogenesis, altered metabolism) which are hallmarks of cancer (Hanahan and Weinberg, Cell 2011, 144(5), 646-674).
- oncogenic KRAS signaling induces the expression of a number of immunomodulatory factors such as TGF13, GM-CSF, CXCL8, Interleukin-6 (IL-6), and IL-10 which interact with the tumor microenvironment to make it immune-suppressive (Cavalho et al Cancer Res 2018, 78(1), 7-14; Cullis et al., Cold Spring Harb. Perspect. Med 8, a031849; Maldegem and Downward, Immunity 2020, 52, 14-16).
- immunomodulatory factors such as TGF13, GM-CSF, CXCL8, Interleukin-6 (IL-6), and IL-10 which interact with the tumor microenvironment to make it immune-suppressive
- Mutant KRAS-driven cancer is known to reprogram the stroma to be pro-tumorigenic (Carvalho et al Cancers 2019, 11(12), 2010) and tumorigenicity is inhibited by interrupting autocrine cytokine signaling (Zhu et al., Cancer Discov 2014, 4, 452-65).
- IL-6 secretion by mutant KRAS tumor cells is known to be upregulated in lung cancer and mediates signaling pathways that promote KRAS-driven lung tumorigenesis (Brooks et al., Cancer Res 2016. 76(4), 1 — 11).
- Mutant KRAS tumor cells secrete vascular endothelial growth factor (VEGF) and other angiogenic factors such as CXC chemokines to initiate angiogenesis is a paracrine process (Matsuo et al Mol Cancer Res 2009, 7(6), 799-808).
- mutant KRAS cells can secrete insulin-like growth factor-1 which increases tumor cell mitochondrial capacity via IGF1R signaling (Tape et al., Cell 2016, 165(4), 910 — 920).
- effective therapies for patients with cancers that have mutant KRAS will need to target the tumor cell as well as the tumor microenvironment.
- SRC kinase has been identified to contribute broadly to cancer treatment resistance including radiotherapy, chemotherapy, and targeted therapy (Zhang S and Yu D. Trends Pharmacol Sci. 2012; 33(3):122-8).
- SRC family kinases can promote mitogenic signaling from growth factor receptors in a number of ways, including initiation of signaling pathways required for DNA synthesis, control of receptor turnover, actin cytoskeleton rearrangements and motility, and survival (Bromann et al, Oncogene 2004; 23(48):7957-68). It was reported that KRAS induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer (Kelber et al, Cancer Res.
- the SRC inhibitor dasatinib was discovered to enhance the anti-tumor activity of MEK inhibitor through inhibition of TAZ activity and the combination of dasatinib and trametinib represents a potential strategy for the treatment of KRAS-driven cancers (Rao et al, Eur J Cancer. 2018 August; 99:37-48).
- FAK plays a vital role in signaling pathways mediated through integrins, RTKs, RAS, and TGF ⁇ (Kanteti et al, Oncotarget. 2016; 7(21):31586-601) and is also likely to suppress p53 expression to promote cell survival (Golubovskaya et al, International Review of Cytology.
- Single-agent Src inhibition promotes a more invasive phenotype through an IL-1 ⁇ >FAK>p130Cas>c-Jun >MMP signaling axis, and the combined inhibition of FAK and Src has the potential to block Src inhibitor-induced phenotype switch and resistance (Kessler et al, Oncogene. 2019; 38:2565-2579).
- Compensatory upregulation of the PI3K/AKT signaling pathway is a resistance mechanism in targeting KRAS mutation, which promotes cancer cell survival.
- FAK through phosphorylated Y397 directly interacts with the SH2 domain of p85, the regulatory subunit of PI3K to activate the PI3K pathway and suppress doxorubicin-induced apoptosis (van Nimwegen et al, Mol Pharmacol. 2006; 70(4):1330-1339).
- Src mediated phosphorylation of FAK at Y925 creates a docking site for GRB2 which activates the small GTP protein RAS and the downstream ERK2 (MAPK) (Kanteti et al, Oncotarget. 2016; 7(21):31586-601).
- Paxillin is a major component of focal adhesions that form a structural link between extracellular matrix and actin cytoskeleton.
- RhoA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.
- KRAS G12C inhibitor AMG-510 are less effective in KRAS G12C mutant colon cancer than in NSCLC (Govindan et al, Annals of Oncology, 2019, 30 (suppl 5): v159-v193. 10.1093/annonc/mdz244).
- mutant KRAS activated p-STAT3 (Tyr705) in the absence of IL-6 secretion, and BCL-XL up-regulation by STAT3 contributes to mutant KRAS-mediated apoptosis resistance in colon cancer (Zaanan et al, J Biol Chem. 2015; 290(39):23838-49). Therefore, inhibition of JAK2 leading to modulation of STAT3 phosphorylation can be used to enable a synergistic apoptotic response in KRAS mutant colon cancer as well as other mutant KRAS cancers.
- Src and FAK regulate STAT3 which controls the expression angiogenetic factors such as VEGF (Niu et al Oncogene 2002, 21(13), 2000 - 8) as well as a range of cytokines (Cavalho et al Cancers 2019, 11(12), 2010).
- Src, FAK, and JAK2 have key roles in mutant KRAS cancer by enabling angiogenesis in tumors, creating a pro-tumor immune response in the tumor microenvironment, and facilitating tumor cell signaling—both tumor cell intrinsic and extrinsic.
- the combined inhibition of Src, FAK, and JAK2 would have additional utility in diseases that have a pro-inflammatory component such as asthma, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and fibrosis.
- the disclosure provides a method for treating cancer in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of one or more compounds that inhibit FAK, SRC and/or JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the host animal is a human patient.
- the host animal is a laboratory animal such as a rodent.
- the disclosure provides a method for treating cancer in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the host animal is a human patient.
- the host animal is a laboratory animal such as a rodent.
- the disclosure provides one of more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the disclosure provides a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the disclosure provides use of one or more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., in the preparation of a medicament comprising a therapeutically effective amount of the compound, for treating cancer in a patient in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the disclosure provides use of a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., in the preparation of a medicament comprising a therapeutically effective amount of the compound, for treating cancer in a patient in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the disclosure provides a composition comprising one or more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., in a therapeutically effective amount, for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the disclosure provides a composition
- a composition comprising a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., in a therapeutically effective amount, for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- the disclosure provides a medicament comprising one or more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., combined with an agent that inhibits KRAS G12C, or a pharmaceutically acceptable salt thereof., in fixed or free combination.
- the disclosure provides a medicament comprising a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., combined with an agent that inhibits KRAS G12C, or a pharmaceutically acceptable salt thereof., in fixed or free combination.
- the disclosure provides a synergistic composition of one or more compounds that inhibit FAK, SRC and/or JAK2 and an agent that inhibits KRAS G12C, where the two components come into contact with each other at a locus.
- the disclosure provides a synergistic composition of a compound that inhibits FAK, SRC and JAK2 and an agent that inhibits KRAS G12C, where the two components come into contact with each other at a locus.
- the disclosure provides a synergistic composition of one or more compounds that inhibit FAK, SRC and/or JAK2, and an agent that inhibits KRAS G12C, where the two components come into contact with each other only in the human body.
- the disclosure provides a synergistic composition of a compound that inhibits FAK, SRC and JAK2, and an agent that inhibits KRAS G12C, where the two components come into contact with each other only in the human body.
- the compound that inhibits FAK, SRC and JAK2 is of the formula
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, -CO2C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OR 7 ;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R 10 ), wherein each R io is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- the compound that inhibits FAK, SRC and JAK2 is of the formula (referred to herein as Compound 1)
- the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule that inhibits KRAS G12C. In some embodiments of the above aspects, the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C. In some embodiments of the above aspects, the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA. In some embodiments of the above aspects, the at least one agent that inhibits KRAS G12C is a small molecule inhibitor.
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R) 1 ° , wherein each R′ ° is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R 10 ), wherein each R io is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R) 1 ° , wherein each R′ ° is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R 10 ), wherein each R io is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R) 1 ° , wherein each R′ ° is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R 10 ), wherein each R io is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R) 1 ° , wherein each R′ ° is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- FIG. 1 a shows the level of caspase-3/7 activated by Compound 1 (1 ⁇ M), AMG-510 (50 nM) and Compound 1 (1 ⁇ M)+AMG510 (50 nM) in H358 cells with KRAS G12C mutation after 24 hrs.
- FIG. 1 B shows the level of caspase-3/7 activated by Compound 1 (1 ⁇ M), AMG-510 (50 nM) and Compound 1 (1 ⁇ M)+AMG510 (50 nM) in H358 cells with KRAS G12C mutation after 48 hrs.
- FIG. 1 c shows the level of caspase-3/7 activated by Compound 1 (1 ⁇ M), AMG-510 (50 nM) and Compound 1 (1 ⁇ M)+AMG510 (50 nM) in H2122 cells with KRAS G12C mutation after 24 hrs.
- FIG. 1 d shows the level of caspase-3/7 activated by Compound 1 (1 ⁇ M), AMG-510 (50 nM) and Compound 1 (1 ⁇ M)+AMG510 (50 nM) in H2122 cells with KRAS G12C mutation after 48 hrs.
- FIG. 1 e shows the level of caspase-3/7 activated by Compound 1 (1 ⁇ M), AMG-510 (50 nM) and Compound 1 (1 ⁇ M)+AMG510 (50 nM) in H1373 cells with KRAS G12C mutation after 24 hrs.
- FIG. if shows the level of caspase-3/7 activated by Compound 1 (1 ⁇ M), AMG-510 (50 nM) and Compound 1 (1 ⁇ M)+AMG510 (50 nM) in H1373 cells with KRAS G12C mutation after 48 hrs.
- FIG. 2 a is a chart showing the 2D dose response matrix after treatment of H2122 cells with a compound 1 and KRAS inhibitor AMG-510 at various concentrations from 0 nM to 3000 nM of Compound 1, and from 0 nM to 10000 nM KRAS inhibitor AMG-510.
- FIG. 2 b is a chart showing the 2D dose response matrix after treatment of H2122 cells with a compound 1 and KRAS inhibitor MRTX849 at various concentrations from 0 nM to 3000 nM of Compound 1, and from 0 nM to 10000 nM KRAS inhibitor MRTX849.
- FIG. 3 a is a graph showing decreased IL-6 secretion in H358 and H2122 NSCLC cell lines treated for 48 h with a combination of Compound 1 with AMG-510.
- FIG. 3 b is a chart showing decreased secretion of IL-6, MCP-1, TGF-01, PDGF-BB, and MIP-3-alpha in H358 cells treated with the combination of Compound 1 and AMG-510 for 48 h.
- FIG. 3 c is a chart showing decreased secretion of IL-6, IGFBP-4 and NAP-2 in H2122 cells treated with the combination of Compound 1 and AMG-510 for 48 h.
- FIG. 3 d is a chart showing decreased secretion of IL-6,GRO, GRO-alpha, IL-10, osteopontin, and osteoprotegerin in H358 cells treated with the combination of Compound 1 and AMG-510 for 24 h.
- FIG. 3 e is a graph showing decreased IL-6 secretion in H2122 NSCLC cell lines treated for 48 h with a combination of Compound 1 with MRTX849.
- FIG. 3 f is an ELISA assay showing decreased IL-6 secretion in H2122 NSCLC cell lines treated for 48 h with a combination of Compound 1 with MRTX849.
- FIG. 3 g is a graph showing the effect of Compound 1 alone, MRTX849 alone, and the combination of Compound 1 and MRTX849 on IL6 mRNA expression from H2122 cells 24 and 48 hrs after treatment.
- FIG. 4 a is a chart showing the antitumor effect of Compound 1 in combination with AMG-510 in H358 cell-derived xenograft tumors harboring a KRAS G12C mutation.
- FIG. 4 b is a chart showing the body weight of mice bearing H358 cell-derived tumors harboring a KRAS G12C mutation when treated with Compound 1 in combination with AMG-510.
- Control ⁇
- Compound 1 (15 mg/kg BID);
- AMG-510 (10 mg/kg QD);
- Compound 1 (15 mg/kg BID) plus AMG-510 (10 mg/kg QD).
- FIG. 5 a is a chart showing the antitumor effect of Compound 1 in combination with AMG-510 in LU11693 PDX model harboring a KRAS G12C mutation.
- the dose of AMG-510 was reduced to 30 mg/kg QD after 14 days of treatment. Two mice in the combination treatment group terminated on day 13.
- FIG. 5 b is a chart showing the body weight of mice bearing LU11693 PDX harboring a KRAS G12C mutation when treated with Compound 1 in combination with AMG-510.
- the dose of AMG-510 was reduced to 30 mg/kg QD after 14 days of treatment. Two mice in the combination treatment group terminated on day 13.
- FIG. 6 a is a chart showing the effect of Compound 1 in combination with AMG-510 on survival in H2122 cell-derived xenograft tumor model harboring a KRAS G12C mutation.
- the dose level of AMG-510 was at 10 mg/kg QD.
- FIG. 6 b is a chart showing the effect of Compound 1 in combination with AMG-510 on survival in H2122 cell-derived xenograft tumor model harboring a KRAS G12C mutation.
- the dose level of AMG-510 was at 30 mg/kg QD.
- a “host animal” can be administered the combinations described herein, and the host animal can be human (e.g., a human patient, a.k.a. a patient) or, in the case of veterinary applications, can be a laboratory, agricultural, or domestic animal.
- the host animal can be a human, or a laboratory animal such as a rodent (e.g., mice, rats, etc.), and the like.
- disease includes, but is not limited to, cancer, pain, inflammatory diseases, such as allergy, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease (e.g. ulcerative colitis), pre-perfusion injury, transplant rejection, psoriasis, and rheumatoid arthritis; polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
- inflammatory diseases such as allergy, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease (e.g. ulcerative colitis), pre-perfusion injury, transplant rejection, psoriasis, and rheumatoid arthritis
- polycythemia vera essential thrombocythemia
- myeloid metaplasia with myelofibrosis e.g., myeloid metaplasia with myelofibro
- cancer includes, but is not limited to, ALCL, lung cancer, such as non-small cell lung cancer (NSCLC), including adenocarcinoma, lung squamous cell carcinoma, large cell carcinoma, and large cell neuroendocrine tumors, small cell lung cancer (SCLC), neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, such as luminal A, luminal B, triple negative breast cancer, triple positive breast cancer, HER2+, and the like, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, thyroid cancer, such as anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, gastric cancer, such as gastric adenocarcinoma, colorectal cancer (CRC), inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic
- NSCLC non-small cell
- cancer includes both primary cancers or primary tumors and metastatic cancers or metastatic tumors, and includes all stages of cancer as known in the art.
- metastatic NSCLC metastatic CRC
- metastatic pancreatic cancer metastatic colorectal carcinoma
- metastatic HNSCC metastatic uterine cancer
- cancer includes cancers that involve the upregulation of certain genes or genetic mutations in certain genes that can lead to disease progression, such as small GTPases (e.g. KRAS and the like) and receptor tyrosine kinases such as EGFR, and the like.
- small GTPases e.g. KRAS and the like
- receptor tyrosine kinases such as EGFR, and the like.
- the term “agent that inhibits KRAS G12C” includes, but is not limited to, any compound or agent known in the art to selectively inhibit the KRAS G12C gene or selectively inhibit the protein encoded by the KRAS G12C gene, referred to herein as K-Ras G12C, that is involved in the RAS/MAPK signaling pathway, where the K-Ras protein product of the KRAS gene has the missense mutation G12C.
- KRAS gene, K-Ras, and RAS/MAPK signaling pathway will be known and understood by one of skill in the art.
- the KRAS G12C mutation encodes a glycine to cysteine mutation at position 12 of the K-Ras protein (a.k.a. K-Ras G12C). It will further be appreciated that the production of a K-Ras G12C protein as a gene product of the KRAS G12C gene can be the result of a coding sequence mutation, e.g. guanine to thymine substitution, at position 34 of the coding sequence.
- a coding sequence mutation e.g. guanine to thymine substitution
- the agent that inhibits KRAS G12C can be any agent known in the art that selectively targets the KRAS G12C gene, and includes those agents, such as siRNA, oligonucleotides, ribonucleic acids, and the like, that selectively inhibit or are capable of otherwise selectively interfering with the transcription (and/or translation) of the KRAS G12C gene (or its corresponding messenger RNA) to the K-Ras G12C protein.
- agents such as siRNA, oligonucleotides, ribonucleic acids, and the like, that selectively inhibit or are capable of otherwise selectively interfering with the transcription (and/or translation) of the KRAS G12C gene (or its corresponding messenger RNA) to the K-Ras G12C protein.
- an agent that inhibits KRAS G12C can be an agent capable of selectively inhibiting or otherwise selectively interfering with KRAS G12C transcription and/or translation of the corresponding messenger RNA can be a biological agent, such as a siRNA, oligonucleotide, ribonucleic acid, and the like.
- an agent that inhibits KRAS G12C can be an agent that selectively inhibits the protein encoded by the KRAS G12C gene having a coding sequence that produces a K-Ras G12C protein (e.g.
- a guanine to thymine substitution, at position 34 of the KRAS coding sequence can be a biological agent, such as an antibody (e.g. a monoclonal antibody or mAb), a small molecule drug/inhibitor (e.g. small molecule inhibitor of KRAS G12C), or a targeted agent.
- an agent that inhibits KRAS G12C can include, but are not limited to AMG-510, MRTX849, JNJ-74699157 (a.k.a. ARS-3248), ARS-1620, MRTX1257, RM-007 or ADT-007.
- the agent that inhibits KRAS G12C is a compound described in United States Patent Publication US20180334454, incorporated herein by reference for exemplary agents that inhibit KRAS G12C (a.k.a. exemplary small molecule inhibitor of KRAS G12C) and their preparation.
- the agent that inhibits KRAS G12C is AMG510 having the formula
- the agent that inhibits KRAS G12C is a compound described in United States Patent Publications US20190270743 and US20190144444, incorporated herein by reference for exemplary agents that inhibit KRAS G12C (a.k.a. exemplary small molecule inhibitor of KRAS G12C) and their preparation.
- the agent that inhibits KRAS G12C is MRTX849 having the formula
- the agent that inhibits KRAS G12C is AMG-510, MRTX849, or ARS-1620, or a pharmaceutically acceptable salt thereof.
- alkyl includes a chain of carbon atoms, which is optionally branched and contains from 1 to 20 carbon atoms. It is to be further understood that in certain embodiments, alkyl may be advantageously of limited length, including C 1 -C 12 , C 1 -C 10 , C 1 -C 9 , C 1 -C 8 , C 1 -C 7 , C 1 -C 6 , and C 1 -C 4 , Illustratively, such particularly limited length alkyl groups, including C 1 -C 8 , C 1 -C 7 , C 1 -C 6 , and C 1 -C 4 , and the like may be referred to as “lower alkyl.” Illustrative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl,
- Alkyl may be substituted or unsubstituted.
- Typical substituent groups include cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, oxo, ( ⁇ O), thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, nitro, and amino, or as described in the various embodiments provided herein.
- alkyl may be combined with other groups, such as those provided above, to form a functionalized alkyl.
- the combination of an “alkyl” group, as described herein, with a “carboxy” group may be referred to as a “carboxyalkyl” group.
- Other non-limiting examples include hydroxyalkyl, aminoalkyl, and the like.
- alkenyl includes a chain of carbon atoms, which is optionally branched, and contains from 2 to 20 carbon atoms, and also includes at least one carbon-carbon double bond (i.e. C ⁇ C). It will be understood that in certain embodiments, alkenyl may be advantageously of limited length, including C 2 -C 12 , C 2 -C 9 , C 2 -C 8 , C 2 -C 7 , C 2 -C 6 , and C 2 -C 4 .
- alkenyl groups including C 2 -C 8 , C 2 -C 7 , C 2 -C 6 , and C 2 -C 4 may be referred to as lower alkenyl.
- Alkenyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
- Illustrative alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like.
- alkynyl includes a chain of carbon atoms, which is optionally branched, and contains from 2 to 20 carbon atoms, and also includes at least one carbon-carbon triple bond (i.e. CC). It will be understood that in certain embodiments, alkynyl may each be advantageously of limited length, including C 2 -C 12 , C 2 -C 9 , C 2 -C 8 , C 2 -C 7 , C 2 -C 6 , and C 2 -C 4 .
- alkynyl groups including C 2 -C 8 , C 2 -C 7 , C 2 -C 6 , and C 2 -C 4 may be referred to as lower alkynyl.
- Alkenyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
- Illustrative alkenyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1—, 2—, or 3-butynyl, and the like.
- aryl refers to an all-carbon monocyclic or fused-ring polycyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-electron system. It will be understood that in certain embodiments, aryl may be advantageously of limited size such as C 6 -C 10 aryl. Illustrative aryl groups include, but are not limited to, phenyl, naphthalenyl and anthracenyl. The aryl group may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
- cycloalkyl refers to a 3 to 15 member all-carbon monocyclic ring, including an all-carbon 5-member/6-member or 6-member/6-member fused bicyclic ring, or a multicyclic fused ring (a “fused” ring system means that each ring in the system shares an adjacent pair of carbon atoms with each other ring in the system) group, where one or more of the rings may contain one or more double bonds but the cycloalkyl does not contain a completely conjugated pi-electron system.
- cycloalkyl may be advantageously of limited size such as C 3 -C 13 , C 3 -C 9 , C 3 -C 6 and C 4 -C 6 .
- Cycloalkyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
- Illustrative cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, adamantyl, norbornyl, norbornenyl, 9H-fluoren-9-yl, and the like.
- Illustrative examples of cycloalkyl groups shown in graphical representations include the following entities, in the form of properly bonded moieties:
- heterocycloalkyl refers to a monocyclic or fused ring group having in the ring(s) from 3 to 12 ring atoms, in which at least one ring atom is a heteroatom, such as nitrogen, oxygen or sulfur, the remaining ring atoms being carbon atoms.
- Heterocycloalkyl may optionally contain 1, 2, 3 or 4 heteroatoms.
- heterocycloalkyl may be advantageously of limited size such as 3- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkyl, and the like.
- Heterocycloalkyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
- heterocycloalkyl groups include, but are not limited to, oxiranyl, thianaryl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, piperazinyl, oxepanyl, 3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl, 1,2,3,4-tetrahydropyridinyl, and the like.
- Illustrative examples of heterocycloalkyl groups shown in graphical representations include the following entities, in the form of properly bonded moieties:
- heteroaryl refers to a monocyclic or fused ring group of 5 to 12 ring atoms containing one, two, three or four ring heteroatoms selected from nitrogen, oxygen and sulfur, the remaining ring atoms being carbon atoms, and also having a completely conjugated pi-electron system. It will be understood that in certain embodiments, heteroaryl may be advantageously of limited size such as 3- to 7-membered heteroaryl, 5- to 7-membered heteroaryl, and the like. Heteroaryl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
- heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, purinyl, tetrazolyl, triazinyl, pyrazinyl, tetrazinyl, quinazolinyl, quinoxalinyl, thienyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and carbazoloyl, and the like.
- Illustrative examples of heteroaryl groups shown in graphical representations include the following entities, in the form of properly bonded
- hydroxy or ““hydroxyl” refers to an —OH group.
- alkoxy refers to both an —O-(alkyl) or an —O-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cycl op entyl oxy, cyclohexyloxy, and the like.
- aryloxy refers to an —O-aryl or an —O-heteroaryl group. Representative examples include, but are not limited to, phenoxy, pyridinyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like.
- mercapto refers to an —SH group.
- alkylthio refers to an —S-(alkyl) or an —S-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
- arylthio refers toh an —S-aryl or an —S-heteroaryl group. Representative examples include, but are not limited to, phenylthio, pyridinylthio, furanylthio, thienylthio, pyrimidinylthio, and the like.
- halo or halogen refers to fluorine, chlorine, bromine or iodine.
- cyano refers to a —CN group.
- oxo represents a carbonyl oxygen.
- a cyclopentyl substituted with oxo is cyclopentanone.
- bond refers to a covalent bond
- substituted means that the specified group or moiety bears one or more substituents.
- unsubstituted means that the specified group bears no substituents.
- substitution is meant to occur at any valency-allowed position on the system.
- substituted means that the specified group or moiety bears one, two, or three substituents.
- substituted means that the specified group or moiety bears one or two substituents.
- substituted means the specified group or moiety bears one substituent.
- each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl is independently optionally substituted by C 1 -C 6 alkyl” means that an alkyl may be but need not be present on any of the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl by
- independently means that the subsequently described event or circumstance is to be read on its own relative to other similar events or circumstances.
- the use of “independently optionally” means that each instance of a hydrogen atom on the group may be substituted by another group, where the groups replacing each of the hydrogen atoms may be the same or different.
- the use of “independently” means that each of the groups can be selected from the set of possibilities separate from any other group, and the groups selected in the circumstance may be the same or different.
- the term “pharmaceutically acceptable salt” refers to those salts which counter ions which may be used in pharmaceuticals. See, generally, S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977, 66, 1-19.
- Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of subjects without undue toxicity, irritation, or allergic response.
- a compound described herein may possess a sufficiently acidic group, a sufficiently basic group, both types of functional groups, or more than one of each type, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- Such salts include:
- Pharmaceutically acceptable salts are well known to those skilled in the art, and any such pharmaceutically acceptable salt may be contemplated in connection with the embodiments described herein.
- Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzo
- any formula depicted herein is intended to represent a compound of that structural formula as well as certain variations or forms.
- a formula given herein is intended to include a racemic form, or one or more enantiomeric, diastereomeric, or geometric isomers, or a mixture thereof.
- any formula given herein is intended to refer also to a hydrate, solvate, or polymorph of such a compound, or a mixture thereof.
- compounds depicted by a structural formula containing the symbol “ ” include both stereoisomers for the carbon atom to which the symbol “ ” is attached, specifically both the bonds “ ” and “ ” are encompassed by the meaning of “ ”.
- certain compounds provided herein can be described by the formula
- the methods described herein relate to the treatment of cancer comprising administering to a patient in need of treatment a therapeutically effective amount of one or more compounds that inhibit FAK, SRC and/or JAK2 in combination with an agent that inhibits KRAS G12C.
- the methods described herein relate to the treatment of cancer comprising administering to a patient in need of treatment a therapeutically effective amount of a compound that inhibits FAK, SRC and JAK2 in combination with an agent that inhibits KRAS G12C.
- an inhibitor is any substance that reduces or suppresses the activity of another substance, such as a cell surface receptor (i.e.
- a compound that inhibits FAK, SRC and JAK2 is a compound that has affinity for all three of the biological targets FAK, SRC and JAK2.
- certain compounds described herein have been surprisingly shown to be inhibitors of FAK, SRC and JAK2, and can be used in combination with an agent that inhibits KRAS G12C to treat cancer in a patient in need of such treatment.
- the combination of one or more compounds that inhibit FAK, SRC and/or JAK2 with an agent that inhibits KRAS G12C can provide a synergistic response in a patient in need of treatment for cancer.
- the combination of a compound that inhibits FAK, SRC and JAK2 with an agent that inhibits KRAS G12C can provide a synergistic response in a patient in need of treatment for cancer.
- methods for treating cancer comprising administering a combination of a therapeutically effective amount of a compound that inhibits FAK, SRC and JAK2 and a therapeutically effective amount of an agent that inhibits KRAS G12C.
- the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are co-formulated.
- the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are administered at the same time.
- the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are individually formulated, and administered at the same time.
- the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are individually formulated, and administered in sequence.
- the sequential administration of the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C can be accomplished with the compound that inhibits FAK, SRC and JAK2 administered first, and the agent that inhibits KRAS G12C administered second.
- the sequential administration of the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C can be accomplished with agent that inhibits KRAS G12C administered first, and the compound that inhibits FAK, SRC and JAK2 administered second.
- the compound that inhibits FAK, SRC and JAK2 is of the formula I
- M is CR 5 or N
- X 1 and X 2 are independently —C(R 7 )(R 8 )—, —S—, —S(O)—, —S(O) 2 —, —O— or —N(R 9 )—;
- each R 1 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)C
- each R 2 and R 3 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, —C(O)OR 7 or —C(O)NR 7 R 8 ; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and C 6 -C 10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , NHC(O)C 1 -C 6 alkyl, —N(C 1 -C 6 alkyl)
- R 4 and R 5 are each independently H, fluoro, chloro, bromo, C 1 -C 6 alkyl, —OH, —CN, —OC 1 -C 6 alkyl, —NHC 1 -C 6 alkyl, —N(C 1 -C 6 alkyl) 2 or —CF 3 ;
- R 6 is H, C 1 -C 6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C 1 -C 6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2 , —CO 2 H, —CO 2 C 1 -C 6 alkyl, —CONH 2 , —CONH(C 1 -C 6 alkyl), —CON(C 1 -C 6 alkyl) 2 , C 3 -C 6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R 7 and R 8 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC 1 -C 6 alkyl, —NH 2 , —NH(C 1 -C 6 alkyl), —N(C 1 -C 6 alkyl) 2
- each R 9 is independently H, deuterium, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C 6 -C 10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl or —OW;
- each Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is independently N, NH, or C(R 10 ), wherein each R io is independently H, deuterium, halogen, C 1 -C 6 alkyl, —O—C 1 -C 6 alkyl, —OH, —NH 2 , —NH(C 1 -C 6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF 3 , and
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 is N or NH;
- R 1 is H or C 1 -C 6 alkyl. In some embodiments, R 1 is H or methyl. In some embodiments, one of R 1 is H and the other of R 1 is methyl. In some embodiments, R 2 is H. In some embodiments, R 2 is C 1 -C 6 alkyl. In some embodiments, one of R 2 is H and the other of R 2 is methyl. In some embodiments, X i is —NR 9 —. In some embodiments, R 9 is H. In some embodiments, X 1 is CHR 7 . In some embodiments, R 7 is H. In some embodiments, X 2 is —O—. In some embodiments, R 6 is H. In some embodiments, R 4 is F. In some embodiments, M is CR 5 , and R 5 is H.
- Macrocyclic compounds that have been shown herein to be potent small-molecule multi-target kinase inhibitors showing activity against FAK, SRC and JAK2 include, but are not limited to, (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one (also herein referred to as “Compound 1”), represented by the formula
- Compound 1 has properties, including anti-tumor properties, which are pharmacologically mediated through inhibition of receptor and non-receptor tyrosine kinases.
- Compound 1 is disclosed in International Patent Publication WO2015/112806, which is incorporated herein by reference for the preparation of Compound 1.
- the compound that inhibits FAK, SRC and JAK2 is of the formula
- the cancer can be any cancer that may be mediated by or associated with KRAS G12C, or the upregulation of KRAS G12C, including but not limited to, ALCL, NSCLC, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblast
- the present disclosure provides methods of treating disease in a patient that has received no prior treatment. In some embodiments, the present disclosure provides methods of treating disease in a patient that has received a prior treatment with one or more therapeutic agents. In some embodiments, the patient has been previously treated with one or more chemotherapeutic agents. In still other embodiments, the patent has been previously treated with one or more chemotherapeutic agents or immunotherapies and developed an acquired resistance to the treatment. In still other embodiments, the patent has been previously treated with one or more chemotherapeutic agents or immunotherapies and developed bypass resistance to the treatment. In still other embodiments, the patent has been previously treated with one or more chemotherapeutic agents or immunotherapies and developed bypass resistance to the treatment regulated by FAK, SRC or JAK2, and/or FAK.
- chemotherapeutic agents which the patient may be been treated with prior to treatment with one or more of the compounds or biological agents described herein include but are not limited to kinase inhibitors, adrenocorticoids and corticosteroids, alkylating agents, peptide and peptidomimetic signal transduction inhibitors, antiandrogens, antiestrogens, androgens, aclamycin and aclamycin derivatives, estrogens, antimetabolites, platinum compounds, amanitins, plant alkaloids, mitomycins, discodermolides, microtubule inhibitors, epothilones, inflammatory and proinflammatory agents, purine analogs, pyrimidine analogs, camptothecins, dolastatins, and or immunotherapies.
- the patient has been administered a prior treatment for NSCLC, such as pembrolizumab, platinum, platinum doublet, pemetrexed, carboplatin, paclitaxel, bevacizumab, atezolizumab, abraxane, and combinations thereof.
- a prior treatment for NSCLC cancer that is the standard of care using one or more agents selected from the group consisting of pembrolizumab, platinum, platinum doublet, pemetrexed, carboplatin, paclitaxel, bevacizumab, atezolizumab, and abraxane.
- the patient has been administered a prior treatment for colorectal cancer, such as fluorouracil (5-FU), leucovorin, irinotecan, oxaliplatin, capecitabine, bevacizumab, cetuximab, panitumumab, ziv-aflibercept, ramucirumab, pemborlizumab, nivolumab, ipilimumab, encorafenib, binimetinib, and combinations thereof.
- the patient has been administered a prior treatment for colorectal cancer that is the standard of care using one or more agents selected from the group consisting of FOLFOX (i.e.
- 5-FU+leucovorin+irinotecan +/ ⁇ bevacizumab, panitumumab or cetuximab
- CAPEOX i.e. oxaliplatin+capecitabine
- FOLFIRI i.e. 5-FU+leucovorin+irinotecan
- cetuximab panitumumab, ziv-aflibercept or ramucirumab
- FOLFOXIRI i.e.
- irinotecan oxaliplatin, leucovorin, 5-FU
- irinotecan+cetuximab panitumumab, or amucirumab
- pemborlizumab pemborlizumab
- nivolumab nivolumab+ipilimumab
- encorafenib and binimetinib.
- the patient has been administered a prior treatment for pancreatic cancer, such as fluorouracil (5-FU), leucovorin, irinotecan, liposomal irinotecan, oxaliplatin, gemcitabine, abraxane, erlotinib, capecitabine, and combinations thereof.
- a prior treatment for pancreatic cancer that is the standard of care using one or more agents selected from the group consisting of FOLFIRINOX (i.e.
- 5-FU+leucovorin+irinotecan+oxaliplatin gemcitabine+abraxane, gemcitabine+erlotinib, gemcitabine, 5-FU+liposomal irinotecan, FOLFIRI (i.e. 5-FU+leucovorin+irinotecan), FOLFOX (i.e. 5-FU, oxaliplatin, leucovorin), and capecitabine+/ ⁇ oxaliplatin.
- the patient has been administered a prior treatment for uterine cancer (a.k.a. endometrial cancer), such as carboplatin, cisplatin, paclitaxel, docetaxel, doxorubicin, liposomal doxorubicin, trastuzumab, topotecan, bevacizumab, temsirolimus tamoxifen, fulvestrant, an aromatase inhibitor, and combinations thereof.
- uterine cancer a.k.a. endometrial cancer
- the patient has been administered a prior treatment for pancreatic cancer that is the standard of care using one or more agents selected from the group consisting of carboplatin+paclitaxel+/ ⁇ trastuzumab, carboplatin or cisplatin+docetaxel, doxorubicin, or paclitaxel, liposomal doxorubicin, topotecan, bevacizumab, temsirolimus tamoxifen, fulvestrant, and an aromatase inhibitor.
- one or more agents selected from the group consisting of carboplatin+paclitaxel+/ ⁇ trastuzumab, carboplatin or cisplatin+docetaxel, doxorubicin, or paclitaxel, liposomal doxorubicin, topotecan, bevacizumab, temsirolimus tamoxifen, fulvestrant, and an aromatase inhibitor.
- agent that inhibits KRAS G12C for use in connection with the combination therapy described herein can be any agent that inhibits KRAS G12C as defined herein.
- agent that inhibits KRAS G12C include antibodies of KRAS G12C, siRNAs, ribonucleic acids, peptides, oligonucleotides, small molecule inhibitors of KRAS G12C (as described herein), and the like.
- the agent that inhibits KRAS G12C can be AMG-510, MRTX849, JNJ-74699157 (a.k.a. ARS-3248), ARS-1620, MRTX1257, RM-007 or ADT-007.
- compositions comprising the compounds described herein may further comprise one or more pharmaceutically-acceptable excipients.
- a pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compounds described herein and are compatible with the active ingredient. Examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, anti-oxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents.
- pharmaceutical compositions according to the invention are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art.
- compositions are also contemplated by the invention, including compositions that are in accord with national and local regulations governing such compositions.
- compositions and compounds described herein may be formulated as solutions, emulsions, suspensions, or dispersions in suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms.
- Pharmaceutical compositions of the invention may be administered by a suitable route of delivery, such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation.
- the compositions are formulated for intravenous or oral administration.
- the compounds the invention may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension.
- the compounds of the invention may be formulated to yield a dosage of, e.g., from about 0.1 mg to 2 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily.
- An alternative exemplary dose is in the range of about from about 0.1 mg/kg to 1 g/kg, or about 0.1 mg/kg to 5 mg/kg, or about 0.1 mg/kg to 1 mg/kg, or about 0.1 mg/kg to 0.6 mg/kg.
- Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
- suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
- Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
- Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents.
- Binding agents may include starch and gelatin.
- the lubricating agent if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
- Capsules for oral administration include hard and soft gelatin capsules.
- active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent.
- Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil, such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
- Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
- suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethyl
- the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
- Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
- Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
- Illustrative infusion doses range from about 1 to 1000 ug/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
- inventive pharmaceutical compositions may be administered using, for example, a spray formulation also containing a suitable carrier.
- inventive compositions may be formulated for rectal administration as a suppository.
- the compounds of the present invention are preferably formulated as creams or ointments or a similar vehicle suitable for topical administration.
- the inventive compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
- Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.
- a therapeutically effective amount of one or more compounds that inhibits FAK, SRC, and/or JAK2 in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C is administered to a host animal, such as a human patient, in need of treatment for cancer.
- a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C is administered to a host animal, such as a human patient, in need of treatment for cancer.
- the term “in combination with” refers to the administration of one or more compounds that inhibits FAK, SRC, and/or JAK2, in particular Compound 1, with at least one agent that inhibits KRAS G12C. It will be appreciated that the administration of one or more compounds that inhibits FAK, SRC, and/or JAK2, in particular Compound 1, “in combination with” administration of at least one agent that inhibits KRAS G12C at the same time as on another, where one or more compounds that inhibits FAK, SRC, and/or JAK2, in particular Compound 1 is administered before at least one agent that inhibits KRAS G12C, or where one or more compounds that inhibits FAK, SRC, and/or JAK2, in particular Compound 1 is administered after at least one agent that inhibits KRAS G12C.
- the administered compounds can be co-formulated in a composition or medicament, or can be administered at the same time as separate compositions or medicaments.
- the term “therapeutically effective amount” refers to that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a patient, which includes alleviation of the symptoms of the disease or disorder being treated. In one aspect, the therapeutically effective amount is that which may treat or alleviate the disease or symptoms.
- the specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient: the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentally with the specific compound employed; and like factors.
- a therapeutically effective amount of the combination can be a synergistic combination that provides an enhanced response to treatment with the combination when compared to when the one or more compounds that inhibits FAK, SRC, and/or JAK2 and the at least one agent that inhibits KRAS G12C are administered individually.
- the synergistic effect provided by the administration of a therapeutically effective amount of the combination of the one or more compounds that inhibits FAK, SRC, and/or JAK2 and the at least one agent that inhibits KRAS G12C is a dose response that is more than additive compared to the response of the each of the components of the combination administered individually.
- a therapeutically effective amount of the combination can be a synergistic combination that provides an enhanced response to treatment with the combination when compared to when the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and the at least one agent that inhibits KRAS G12C are administered individually.
- the synergistic effect provided by the administration of a therapeutically effective amount of the combination of the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and the at least one agent that inhibits KRAS G12C is a dose response that is more than additive compared to the response of the each of the components of the combination administered individually.
- an exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g. It will be appreciated that all possible subranges within the dose ranges described above are contemplated and described herein.
- a dose range of about 150 to about 500 mg for a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, provided in the methods and compositions described herein includes doses of about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, including all possible doses and ranges as may be required based on such factors for determining a therapeutically effective amount as described herein.
- an exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg to about 3 g daily, or about 1 mg to about 50 mg daily, or about 50 to about 250 mg daily, or about 150 to about 500 mg daily, or about 150 to about 250 mg daily, or about 250 mg to about 1 g daily, or about 100 mg to about 2 g daily, or about 500 mg to about 2 g daily, or about 500 mg to about 1 g daily. It will be appreciated that all possible subranges within the daily dose ranges described above are contemplated and described herein.
- a dose range of about 150 to about 500 mg daily for a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, provided in the methods and compositions described herein includes doses of about 150 mg daily, about 160 mg daily, about 170 mg daily, about 180 mg daily, about 190 mg daily, about 200 mg daily, about 210 mg daily, about 220 mg daily, about 230 mg daily, about 240 mg daily, and about 250 mg daily, about 260 mg daily, about 270 mg daily, about 280 mg daily, about 290 mg daily, about 300 mg daily, about 310 mg daily, about 320 mg daily, about 330 mg daily, about 340 mg daily, about 350 mg daily, about 360 mg daily, about 370 mg daily, about 380 mg daily, about 390 mg daily, about 400 mg daily, about 410 mg daily, about 420 mg daily, about 430 mg daily, about 440 mg daily, about 450 mg daily, about 460 mg daily, about 470 mg daily, about 480 mg daily, about 490 mg daily, about 500 mg daily
- an alternative exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg. It will be appreciated that all possible subranges within the dose ranges described above are contemplated and described herein.
- a dose range of about 1.0 mg/kg to about 10 mg/kg for a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, provided in the methods and compositions described herein includes doses of about 1.0 mg/kg, about 2.0 mg/kg, about 3.0 mg/kg, about 4.0 mg/kg, about 5.0 mg/kg, about 6.0 mg/kg, about 7.0 mg/kg, about 8.0 mg/kg, about 9.0 mg/kg, and about 10.0 mg/kg, including all possible doses and ranges as may be required based on such factors for determining a therapeutically effective amount as described herein.
- an alternative exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg/kg to about 1 g/kg daily, or about 0.5 mg/kg to about 50 mg/kg daily, or about mg/kg to about 25 mg/kg daily, or about 1.0 mg/kg to about 10 mg/kg daily, or about 1.0 mg/kg to about 5 mg/kg daily, or about 0.1 mg/kg to about 5 mg/kg daily, or about 0.1 mg/kg to about 1 mg/kg daily, or about 0.1 mg/kg to about 0.6 mg/kg daily. It will be appreciated that all possible subranges within the dose ranges described above are contemplated and described herein.
- a dose range of about 1.0 mg/kg to about 10 mg/kg daily for a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, provided in the methods and compositions described herein includes doses of about 1.0 mg/kg daily, about 2.0 mg/kg daily, about 3.0 mg/kg daily, about 4.0 mg/kg daily, about 5.0 mg/kg daily, about 6.0 mg/kg daily, about 7.0 mg/kg daily, about 8.0 mg/kg daily, about 9.0 mg/kg daily, and about 10.0 mg/kg daily, including all possible doses and ranges as may be required based on such factors for determining a therapeutically effective amount as described herein.
- a dosing schedule for each compound or agent administered individually (or together) in the various methods and compositions described herein can be defined by cycles of the dosing schedule, where such cycles are defined by the number of days of treatment, number of doses of each compound or agent individually (or together), the total dose of each compound or agent individually (or together), and the like.
- a host animal such as a human patient in need of treatment, can be administered each compound or agent administered individually (or together) for at least one cycle, for at least two cycles, for at least three cycles, for at least four cycles, and the like.
- a host animal such as a human patient in need of treatment
- a dosing schedule for each compound or agent administered individually (or together) in the various methods and compositions described herein can include a holiday period during which no compound or agent is administered, and such holiday period can be measured in days.
- a dosing schedule for each compound or agent administered individually (or together) in the various methods and compositions described herein can be defined by a number of cycles as described herein, followed by a holiday period, followed by another number of cycles as described herein.
- an exemplary dosing schedule for each compound or agent individually in the various methods and compositions described herein can include administration of a single daily dose (QD) or divided dosage units (e.g., BID (twice daily), TID (three times daily), QID (four times daily)).
- QD single daily dose
- divided dosage units e.g., BID (twice daily), TID (three times daily), QID (four times daily)
- a dosing schedule for each compound or agent in the various methods and compositions described herein can be the same, such as all compounds or agents in the various methods and compositions described herein are administered QD, BID, or the like.
- a dosing schedule for each compound or agent in the various methods and compositions described herein can be different from each other, such as one compound or agent in the various methods and compositions described herein is administered QD, and another compound or agent in the various methods and compositions described herein is administered BID.
- a dosing schedule for each compound or agent in the various methods and compositions described herein can vary within a cycle, such as one compound or agent in the various methods and compositions described herein administered QD for a set number of days (e.g. QD for 1 day, 2 days, 3 days, 4 days, etc) followed by BID for a set number of days (e.g. BID for 1 day, 2 days, 3 days, 4 days, etc).
- a dosing schedule for each compound or agent in the various methods and compositions described herein can be the same or different within a cycle, such as one compound or agent in the various methods and compositions described herein administered QD for a set number of days (e.g. QD for 1 day, 2 days, 3 days, 4 days, etc) followed by BID for a set number of days (e.g. BID for 1 day, 2 days, 3 days, 4 days, etc) to match the length of the cycle, and another compound or agent administered BID for a set number of days to match the length of the cycle.
- QD a set number of days
- BID a set number of days
- BID for 1 day, 2 days, 3 days, 4 days, etc
- the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and the agent that inhibits KRAS G12C are administered at the same time. In some embodiments, the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and the agent that inhibits KRAS G12C are individually formulated, and administered at the same time. In some embodiments, the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and the agent that inhibits KRAS G12C are individually formulated, and administered in sequence.
- the sequential administration of the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and the agent that inhibits KRAS G12C can be accomplished with the compound that inhibits FAK, SRC and JAK2, in particular Compound 1, administered first (e.g. in the morning), and the agent that inhibits KRAS G12C administered second (e.g. in the afternoon or evening).
- the sequential administration of the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and the agent that inhibits KRAS G12C can be accomplished with agent that inhibits KRAS G12C administered first (e.g. in the morning), and the compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, administered second (e.g. in the afternoon or evening).
- an exemplary dosing schedule for each compound or agent individually in the various methods and compositions described herein can include administration of a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, at a dose level of from about 100 mg to about 300 mg QD for at least one day followed by a dose level of from about 100 mg to about 300 mg BID and an agent that inhibits KRAS G12C, in particular AMG510, at a dose level of from about 800 mg to about 1.5 g QD.
- the administration of a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and an agent that inhibits KRAS G12C, in particular AMG510, on the dose schedule described above can be given for from 1 to about 20 cycles, where each cycle is from about 5 to about 20 days.
- the administration of a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and an agent that inhibits KRAS G12C, in particular AMG510, on the dose schedule described above can be given for a set number of days, such as from about 20 to about 200 days, perpetually, or until treatment is stopped by a treating physician.
- an exemplary dosing schedule for each compound or agent individually in the various methods and compositions described herein can include administration of a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, at a dose level of from about 100 mg to about 300 mg QD for at least one day followed by a dose level of from about 100 mg to about 300 mg BID and an agent that inhibits KRAS G12C, in particular MRTX849, at a dose level of from about 500 mg to about 1 g BID.
- the administration of a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and an agent that inhibits KRAS G12C, in particular MRTX849, on the dose schedule described above can be given for from 1 to about 20 cycles, where each cycle is from about 5 to about 20 days.
- the administration of a compound that inhibits FAK, SRC, and JAK2, in particular Compound 1, and an agent that inhibits KRAS G12C, in particular MRTX849, on the dose schedule described above can be given for a set number of days, such as from about 20 to about 200 days, perpetually, or until treatment is stopped by a treating physician.
- AMG510 was purchased from Active Biochem (catalog number A-9132). Drugs were prepared in dimethyl sulfoxide (DMSO) at a concentration of 10-100 mmol/L stock solutions and stored at ⁇ 20° C. Further dilutions were made in culture medium to final concentration before use.
- DMSO dimethyl sulfoxide
- Phospho—STAT3 (Tyr705), phospho-AKT (Ser473), phospho-ERK1/2 (Thr202/Tyr204), phospho-FAK (Tyr576/577), STAT3, FAK, SRC, AKT, ERK, PARP, cleaved caspase-3, tubulin, and actin were purchased from Cell Signaling Technology (Beverly, MA).
- Results showing cell viability % of the KRAS G12C inhibitor (AMG510), Compound 1, and the combination of the KRAS inhibitor AMG510 with Compound 1 (1 ⁇ M) in KRAS G12C mutated H358, H23, H2122, H1373 and H1792 cells are summarized in Table 1.
- H358, H23, H2122, H1373 and H1792 NSCLC cell line endogenously expresses KRAS G12C mutation the KRAS G12C inhibitor AMG510 demonstrated moderate to weak inhibition of the cell proliferation.
- Compound 1 at 11.04 concentration shifted AMG510′s IC 50 from 213nM to 3 nM against H358 cell proliferation.
- the combination caused much more complete cell proliferation suppression compared to AMG510 treatment alone in H23, H2122, H1372, and H1792 NSCLC cell lines harboring the KRAS G12C mutation.
- Results showing cell viability % of the KRAS G12C inhibitor MRTX849, Compound 1, and the combination of the KRAS inhibitor MRTX849 with Compound 1 (1 ⁇ M) in KRAS G12C mutated H358, and H2122 cells were also determined.
- Compound 1 at 1 ⁇ M concentration shifted MRTX849's IC 50 from 75nM to 11 nM against H358 cell proliferation and from 182 nM to 42 nM against H2122 cell proliferation.
- Results showing cell viability % of the KRAS G12C inhibitor ARS-1620, Compound 1, and the combination of the KRAS inhibitor ARS-1620 with Compound 1 (1 ⁇ M) in KRAS G12C mutated H358, and H2122 cells were determined.
- Compound 1 at 1 ⁇ M concentration shifted ARS-1620's IC 50 from 488 nM to 88 nM against H358 cell proliferation and from 1287 nM to 52 nM against H2122 cell proliferation.
- Compound 1 alone increased caspase-3/7 activity in H358 and H2122 NSCLC cell lines ( FIGS. 1 a - 1 d ).
- AMG510 alone increased caspase-3/7 activity with H358, H2122, and H1373 NSCLC cell lines ( FIGS. 1 a - 1 f ).
- the combination of Compound 1 with AMG510 caused more caspase-3/7 activation compared to AMG510 treatment alone for NSCLC cells with a G12C mutation ( FIGS. 1 a - 1 f ) at both 24 and 48 hour timepoints.
- Cleaved PARP and cleaved caspase-3 were evaluated as biomarkers of apoptosis.
- Half a million cells per well were seeded in 24 well plate for 24 hrs, and then treated with compounds for 4, 24 or 48 hours.
- Cells were collected after treatment and lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS) supplemented with 10 mM EDTA, 1 ⁇ Halt protease and phosphatase inhibitors (Thermo Scientific).
- Protein lysates (approximately 20 pg) was resolved on 4-12% Bolt Bis-Tris precasted gels with MES running buffer (Life Technologies), transferred to nitrocellulose membranes using Trans-Blot Turbo Transfer System (Bio-Rad) and detected with antibodies targeting PARP, Cleaved caspase-3, tubulin and actin (Cell Signaling Technology). Antibodies were typically incubated overnight at 4° C. with gentle shake, followed by washes and incubation with the appropriate HRP-conjugated secondary antibodies. Membranes were incubated with chemiluminescent substrate for 5 min at room temperature (SuperSignal West Femto, Thermo Scientific).
- results in the H358 KRAS G12C NSCLC cell line demonstrated large increases in cleaved PARP and cleaved caspase-3 after both 24 and 48 hour treatments with the combination of AMG510 (100 nM) and Compound 1 (1 Treatment with AMG510 alone (100 nM) or Compound 1 alone (1 ⁇ M) resulted in small increases in cleaved PARP and cleaved caspase-3 protein.
- Activation of apoptosis was demonstrated by cleaved PARP and cleaved caspase-3 in H358 mutant KRAS G12C NSCLC cells after 24 hr or 48 hr with AMG510 (100 nM), Compound 1 (1 ⁇ M), and the combination of AMG510 (100 nM) and Compound 1 (1 ⁇ M) after 48 hrs.
- Results in H2122 KRAS G12C NSCLC demonstrated large increases in cleaved PARP and cleaved caspase-3 after 48 hour treatment with the combination of AMG510 (100 nM) and Compound 1 (1
- Treatment with AMG510 (100 nM) alone or Compound 1 (1 ⁇ M) alone had minimal-to-no increases in increased cleaved PARP and cleaved caspase-3 which was strikingly less than the combination of Compound 1 and AMG510.
- Protein lysates (approximately 20 pg) was resolved on 4-12% Bolt Bis-Tris precasted gels with IVIES running buffer (Life Technologies), transferred to nitrocellulose membranes using Trans-Blot Turbo Transfer System (Bio-Rad) and detected with antibodies targeting phosphorylated STAT3, FAK, SRC, HER2, AKT, ERK, S6 (Cell Signaling Technology), total STAT3, FAK, SRC, HER2, AKT, S6 ERK and cleaved caspase 3 (Cell Signaling Technology). Antibodies were typically incubated overnight at 4° C. with gentle shake, followed by washes and incubation with the appropriate HRP-conjugated secondary antibodies.
- Membranes were incubated with chemiluminescent substrate for 5 min at room temperature (SuperSignal West Femto, Thermo Scientific). The chemiluminescent images were acquired with a C-DiGit Imaging System (LI-COR Biosciences). The inhibition of phosphorylation of STAT3, ERK, AKT, and FAK by Compound 1 (1 ⁇ M), AMG510 (100 nM), and Compound 1 (1 ⁇ M)+AMG510 (100 nM) was measured after 4, 24, and 48 hrs.
- Results in H358 KRAS G12C NSCLC showed that Compound 1 alone suppressed protein levels of phospho—STAT3 (pSTAT3), phospho-FAK (pFAK) at 4, 24 and 48 h time points.
- AMG510 did not suppress pSTAT3 or pFAK protein levels at any time point.
- the combination of Compound 1 and AMG510 suppressed pFAK and pSTAT3 protein levels at all time points.
- Compound 1 alone did not suppress phospho-ERK (PERK) at any time point.
- AMG510 did not suppress pERK at 4 hours of treatment but does after 24 and 48 hours of treatment.
- the combination of Compound 1 with AMG510 suppressed pERK at all timepoints.
- MRTX849 did not suppress pSTAT3, pFAK or pSRC protein levels at any time point.
- the combination of Compound 1 and MRTX849 suppressed pFAK, pSTAT3 and pSRC protein levels at all time points.
- Compound 1 alone did not suppress phospho-ERK (pERK) at any time point while MRTX849 suppresses pERK at all time points.
- the combination of Compound 1 with MRTX849 suppressed pERK at all timepoints.
- Treatment with Compound 1 alone or MRTX849 alone suppressed phospho-AKT (pAKT) at all time points.
- Treatment of 48 hours with MRTX849 alone increased pHER2.
- H358 mutant KRAS G12C NSCLC cells The inhibition of phosphorylation of FAK, STAT3, SRC, ERK, AKT, and S6 by Compound 1 (1 ⁇ M), ARS1620 (1 ⁇ M), and Compound 1 (1 ⁇ M)+ARS1620 (1 ⁇ M) was evaluated in H358 mutant KRAS G12C NSCLC cells after 4 hrs, 24 hrs and 48 hrs. Results in H358 KRAS G12C NSCLC show that Compound 1 alone suppressed protein levels of phospho-STAT3 (pSTAT3), phospho-FAK (pFAK) and phospho—SRC at 4, 24 and 48 h time points. ARS1620 did not suppress pSTAT3, pFAK or pSRC protein levels at any time point.
- the combination of Compound 1 and ARS1620 suppressed pFAK, pSTAT3 and pSRC protein levels at all time points.
- the combination of Compound 1 with ARS1620 suppressed pERK at all timepoints.
- Treatment with Compound 1 alone or ARS1620 alone suppressed phospho-AKT (pAKT) with treatments up to 24 hours.
- Treatment of 48 hours with ARS1620 alone increased pAKT while 48 treatment with Compound 1 alone decrease pAKT relative to control.
- the combination of Compound 1 with ARS1620 had significant suppression of pAKT and p-S6.
- Results in H2122 KRAS G12C NSCLC show that Compound 1 alone suppressed protein levels of phospho-STAT3 (pSTAT3), phospho-FAK (pFAK) and phospho—SRC at 4, 24 and 48 h time points.
- ARS1620 did not suppress pSTAT3, pFAK or pSRC protein levels at any time point.
- the combination of Compound 1 and ARS1620 suppressed pFAK, pSTAT3 and pSRC protein levels at all time points.
- Compound 1 alone did not suppress phospho-ERK (pERK) at any time point while ARS1620 suppressed pERK at 4 and 24 hours.
- the combination of Compound 1 with ARS1620 suppressed pERK at at 4 and 24 hours.
- the combination of Compound 1 with ARS1620 showed significant enhanced suppression of pAKT and p-S6 than ARS1620 treatment alone.
- H2122 NSCLC cells were used to identify synergistic combinations between AMG-510 or MRTX-849 and Compound 1.
- One 96-well plate was seeded with 2000 cells/well in a total volume of 80 ⁇ 1 of RPMI supplemented with 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- a combination matrix was generated comprising a horizontally diluted drug titration of AMG-510 or MRTX-849 (final concentration of 10 ⁇ M diluted 3-fold down to 1.5 nM) with a vertically titrated Compound 1 (final concentration of 3 ⁇ M to 37 nM diluted 3 fold).
- the cells were incubated for 96 hours at 37C in 5% CO 2 .
- KRAS inhibitors AMG-510 and MRTX-849
- Compound 1 demonstrated synergy in H2122 cells.
- a visualization of the dose response matrix are shown in FIGS. 2 a - 2 b .
- Table 2 shows the Bliss synergy scores for relevant drug doses.
- ENA-78 CXCL5, GCSF, GM-CSF, GRO alpha/beta/gamma, GRO alpha (CXCL1), I-309 (TCA-3/CCL1), IL-1 alpha (IL-1 F1), IL-1 beta (IL-1 F2), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12 p40/p70, IL-13, IL-15, IFN-gamma, MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (MARC/CCL7), M-CSF, MDC (CCL22), MIG (CXCL9), MIP-1 beta (CCL4), MIP-1 delta (CCL15), RANTES (CCL5), SCF, SDF-1 alpha (CXCL12 alpha), TARC (CCL17), TGF beta 1, TNF alpha, TNF beta (TNFSF1B), EGF
- Cytokines present in NCI-H358 and NCI-H2122 conditioned media were identified and quantitatively compared using Human Cytokine Antibody Array C 5 (AAH-CYT-5-8, RayBiotech).
- AAH-CYT-5-8 Human Cytokine Antibody Array C 5
- One million cells per well were seeded in 6 well plates and allowed to attach for 24 h, and then treated with AMG-510 (100 nM)/MRTX849 (100 nM), Compound 1 (1 ⁇ M) or the combination of AMG-510 (100 nM)/MRTX849 (100 nM) and Compound 1 (1 ⁇ M) for 24 or 48 hours.
- Antibody arrays were blocked for 30 minutes at room temperature, following incubation with conditioned media from H358 and H2122 cells overnight at 4° C.
- Antibody arrays were then washed and re-incubated with the biotinylated antibody cocktail overnight at 4° C., followed with HRP-conjugated streptavidin for 2 h at room temperature. Following a final wash step, chemiluminescence detection buffers were added to arrays and chemiluminescence signals were captured using a iBright 1500 imaging system (Invitrogen). The spot density was quantified by using the iBright Analysis Software and compared using the RayBiotech Analysis tool for AAH-CYT-5.
- Half a million cells per well were seeded in 6 well plates and allowed to attach for 24 hrs, and then treated with AMG-510 (100 nM)/MRTX849 (100 nM), Compound 1 (1 ⁇ M) or the combination of AMG-510 (100 nM)/MRTX849 (100 nM) and Compound 1 (1 ⁇ M) for 48 hours.
- AMG-510 100 nM/MRTX849 (100 nM)
- Compound 1 (1 ⁇ M) Compound 1 (1 ⁇ M
- To assess IL-6 secretion by tumor cells supernatants were harvested and human IL-6 ELISA assays were performed per manufacturer's instructions (R&D Biosystems). Briefly, microplate wells were incubated with either the standard, control and sample supernatants from H358 and H2122 cells for 2 hours at room temperature.
- Microplates were then washed and incubated with human IL-6 conjugate for 2 hours at room temperature, followed by washing and addition of substrate solution for 20 minutes. Finally stop solution is added and optical density evaluated using a microplate reader set to 450 nm. Readings at 540 nm were substracted to correct for optical imperfections in the plate.
- Half a million cells per well were seeded in 6 well plates and allowed to attach for 24 hrs, and then treated with AMG-510 (100 nM)/ MRTX849 (100 nM), Compound 1 (1 ⁇ M) or the combination of AMG-510 (100 nM)/MRTX849 (100 nM) and Compound 1 (1 ⁇ M) for 24 and 48 hours.
- mRNA was prepared using the Rneasy Mini Kit (Qiagen) and cDNA synthesized using SuperScript IV VILO (Invitrogen). qPCR was carried out with diluted cDNA, appropriate Taqman probes and Taqman Fast Advanced Master mix (Applied Biosystems) using a QuantStudio 5 Thermal Cycler (Applied Biosystems). Relative mRNA levels were calculated using the 2-Ct method, using RPL32 as an internal control.
- KRAS cell lines H358 and H2122 shown to secrete IL-6
- IL-6 is shown to be inhibited by Compound 1 alone and in the presence of AMG510, where the inhibition of IL-6 secretion is greater in the combination of Compound 1 and AMG-510, than with either compound individually. Results are shown in FIGS. 3 a - 3 d.
- Cytokine data was also generated in H2122 NSCLC cell lines treated for 48 h with a combination of Compound 1 with MRTX849.
- mice Female athymic nude, SCID, NOD/SCID or SCID/Beige mice (5-8 weeks of age) were used as host mice.
- SCID subcutaneous cell-derived xenograft models
- matrigel Matrigel
- a tumor fragment from host mice was implanted subcutaneously in the flank region of each host mouse. Tumor size and body weight were measured on designated days. Tumor size was measured with an electronic caliper and tumor volume was calculated as the product of length*width 2*0.5 or similar formula.
- mice were randomized by tumor size into treatment groups when mean tumor volume reached a certain size.
- Compound 1 was administered orally twice a day at determined doses and AMG-510 was administered orally once a day at determined doses.
- For brain orthotopic models about 80000 cells were implanted into brain and treatment of mice with control or test articles started 7 days post the implantation.
- mice bearing xenograft tumors were humanely euthanized and tumors were resected and snap frozen in liquid nitrogen and stored at ⁇ 80° C. Frozen tumor samples were processed at 4° C. in RIPA buffer to extract proteins. Protein concentration of the lysate was determined by Rapid Gold BCA Protein Assay (Life Technologies, Inc.) and lysate were diluted to ensure the same protein concentration across samples. SDS loading samples were prepared by adding one volume of 4 ⁇ LDS Sample Buffer (Life Technologies, Inc.) to three volumes of diluted protein lysate. Tumor SDS protein samples were processed by SDS-PAGE and immunoblotted appropriate primary antibodies, followed by detection using HRP conjugated secondary antibodies. The signals from immunoblot were detected by C-DiGit Blot Scanner from LI-COR using the Image Studio Digit software (LI-COR).
- H358 cells harbor a KRAS G12C mutation.
- SCID/Beige mice bearing H358 cell-derived tumors were treated with vehicle BID, Compound 1 BID at 15 mg/kg, AMG-510 QD at 10 mg/kg, and Compound 1 BID at 15 mg/kg in combination with AMG-510 QD at 10 mg/kg, respectively.
- the tumor volume (TMV) vs time data are shown as mean ⁇ sem in FIG. 4 a .
- Compound 1 in combination with AMG-510 significantly reduced tumor volume compared to the treatment with vehicle, Compound 1 only or AMG-510 only (p ⁇ 0.0001 for all three comparisons, post hoc Tukey's multiple comparison test following two-way repeated measures ANOVA analysis).
- tumor lysate was prepared and analyzed by immunoblotting using antibodies against the candidate molecules selected from signaling pathways that can be potentially modified by Compound 1 and/or AMG-510.
- the inhibitory activities of Compound 1 against SRC and JAK2 were demonstrated by the reduction of phosphorylated SRC (Y416) and STAT3 (Y705) signals in tumors treated by Compound 1 either as the single agent or in combination with AMG-510, compared to vehicle treatment.
- the activity of Compound 1 against FAK was shown by the reduced the phosphorylated FAK signal in Compound 1 and AMG-510 combination treatment group.
- AMG-510 activity against KRAS was illustrated by the reduced level of phosphorylated ERK (T202/Y204) signal, a key downstream effector of KRAS signaling in mice treated by AMG-510 either as a single agent or in combination with Compound 1.
- combination of Compound 1 with AMG-510 also reduced the phosphorylated AKT (S473) signal, a key factor involved in cell survival and proliferation. Therefore, Compound 1 and AMG-510 combinatory treatment not only Compound 1 and AMG-510 targets, including SRC, FAK, JAK2, and KRAS, but also suppress the activity of AKT, a key factor for the PI3K-AKT oncogenic pathway.
- LU11693 PDX tumors harbor a KRAS G12C mutation.
- NOD/SCID mice bearing LU11693 PDX tumors were treated with vehicle BID, Compound 1 BID at 15 mg/kg, AMG-510 QD at 100 mg/kg, and Compound 1 BID at 15 mg/kg in combination with AMG-510 QD at 100 mg/kg, respectively.
- the tumor volume vs time data are shown as mean ⁇ sem in FIG. 5 a .
- Body weight of the mice were measured during treatment and are shown as mean ⁇ sem in FIG. 5 b .
- Treatment with AMG-510 at 100 mg/kg QD either as a single agent or in combination with Compound 1 significantly reduced body weight of mice.
- the median survival were 34, 52, 77, and 76.5 days for the groups treated with vehicle BID, Compound 1 BID at 15 mg/kg, AMG-510 QD at 10 mg/kg, Compound 1 BID at 15 mg/kg in combination with AMG-510 QD at mg/kg, and AMG-510 QD at 30 mg/kg, respectively; and the median survival was not reached for the group treated with Compound 1 BID at 15 mg/kg in combination with AMG-510 QD at 30 mg/kg when the study was terminated on day 101 post the tumor cell implantation.
Abstract
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
Description
- This application is a continuation of U.S. application Ser. No. 17/104,752, filed Nov. 25, 2020 which claims priority to U.S. Provisional Application No. 62/941,026, filed Nov. 27, 2019; U.S. Provisional Application No. 62/981,822, filed Feb. 26, 2020; and U.S. Provisional Application No. 63/005,681, filed Apr. 6, 2020, each of which is incorporated herein in its entirety for all purposes.
- The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with a KRAS inhibitor, such as an inhibitor of KRAS G12C.
- Kirsten Rat Sarcoma Viral Oncogene homolog KRAS is one of three RAS protein family members (N, H, and K-RAS) that are small membrane bound intracellular GTPase proteins. KRAS cycles between an inactive guanosine diphosphate (GDP)-bound state and an active guanosine triphosphate (GTP)-bound state. Active GTP-bound KRAS interacts with numerous effectors to stimulate multiple signaling pathways (e.g. PI3K-AKT-MTOR, RAF-MEK-ERK) to affect a range of cellular processes (e.g. survival, proliferation, cytoskeletal organization).
- KRAS is one of the most frequently mutated oncogenes across a broad spectrum of human cancers (18%, Catalogue of Somatic Mutations in Cancer (COSMIC) database v90), including non-small cell lung, colorectal, pancreatic, uterine, bladder, stomach, renal, breast, skin, prostate, acute myeloid leukemia, cervical, liver acute lymphoblastic leukemia, ovarian, and brain cancers. KRAS mutations primarily occur in
KRAS codons codons 18, 61, 117, and 146 at low frequencies and have distinct effects on tumor cell signaling based on the codon and missense mutation (Stolze et al. Sci Rep. 2015; 5:8535). - Direct targeting of a single KRAS mutation G12C through a covalent modality has produced a range of preclinical outcomes from insensitive to responsive in mouse tumor models that have the KRAS G12C mutation (Ostrem et al, Nature. 2013, 503(7477):548-51). Tumor regression has been reported in the treatment of patients with KRAS G12C mutated non-small cell lung cancer or colorectal cancer with KRAS G12C inhibitors AMG510 (Canon et al, Nature, 2019, 575, 217-223) and MRTX849 (Hallin et al, Cancer Discovery, 2020, 10(1) 54-71) in clinical studies. However, intrinsic and acquired resistance are expected to limit KRAS inhibitors used as a single agent in clinical application because of the development of signaling adaptation or selection of minor variants. KRAS G12C inhibitor MRTX849 demonstrated tumor regression in only 17 of 26 (65%) of KRAS G12C-positive cell line- and patient-derived mouse xenograft models from multiple tumor types and multiple resistance mechanisms including KRAS nucleotide cycling and feedback reactivation and/or bypass KRAS dependence limit the efficacy and duration of response of MRTX849 in non-clinical models (Hallin et al, Cancer Discovery, 2020, 10(1), 54-71). Covalent inhibitors of KRAS G12C have been reported to be more effective when combined with immune checkpoint inhibitory monoclonal antibodies such as those that block the programmed death-1 (PD-1) (Canon et al, Nature, 2019, 575, 217-223). Combinations that target MAPK pathway feedback re-activation, RTK-induced PI3K pathway activation, increased apoptosis, and suppress the proinflammatory tumor microenvironment will be necessary to provide significant improvements in clinical benefit.
- Tumor cells reprogram the tumor microenvironment by many processes (e.g. immune suppression, induction of angiogenesis, altered metabolism) which are hallmarks of cancer (Hanahan and Weinberg, Cell 2011, 144(5), 646-674). Many studies show that oncogenic KRAS signaling induces the expression of a number of immunomodulatory factors such as TGF13, GM-CSF, CXCL8, Interleukin-6 (IL-6), and IL-10 which interact with the tumor microenvironment to make it immune-suppressive (Cavalho et al Cancer Res 2018, 78(1), 7-14; Cullis et al., Cold Spring Harb. Perspect. Med 8, a031849; Maldegem and Downward, Immunity 2020, 52, 14-16). Mutant KRAS-driven cancer is known to reprogram the stroma to be pro-tumorigenic (Carvalho et al Cancers 2019, 11(12), 2010) and tumorigenicity is inhibited by interrupting autocrine cytokine signaling (Zhu et al., Cancer Discov 2014, 4, 452-65). One example is IL-6 secretion by mutant KRAS tumor cells. IL-6 is known to be upregulated in lung cancer and mediates signaling pathways that promote KRAS-driven lung tumorigenesis (Brooks et al., Cancer Res 2016. 76(4), 1 — 11). Mutant KRAS tumor cells secrete vascular endothelial growth factor (VEGF) and other angiogenic factors such as CXC chemokines to initiate angiogenesis is a paracrine process (Matsuo et al Mol Cancer Res 2009, 7(6), 799-808). Other paracrine processes remodel the stroma as well as alter tumor cell processes in addition to immune evasion and angiogenesis. For example, mutant KRAS cells can secrete insulin-like growth factor-1 which increases tumor cell mitochondrial capacity via IGF1R signaling (Tape et al., Cell 2016, 165(4), 910 — 920). As such, effective therapies for patients with cancers that have mutant KRAS will need to target the tumor cell as well as the tumor microenvironment.
- SRC kinase has been identified to contribute broadly to cancer treatment resistance including radiotherapy, chemotherapy, and targeted therapy (Zhang S and Yu D. Trends Pharmacol Sci. 2012; 33(3):122-8). SRC family kinases can promote mitogenic signaling from growth factor receptors in a number of ways, including initiation of signaling pathways required for DNA synthesis, control of receptor turnover, actin cytoskeleton rearrangements and motility, and survival (Bromann et al, Oncogene 2004; 23(48):7957-68). It was reported that KRAS induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer (Kelber et al, Cancer Res. 2012; 72(10):2554-64). The SRC inhibitor dasatinib was discovered to enhance the anti-tumor activity of MEK inhibitor through inhibition of TAZ activity and the combination of dasatinib and trametinib represents a potential strategy for the treatment of KRAS-driven cancers (Rao et al, Eur J Cancer. 2018 August; 99:37-48). FAK plays a vital role in signaling pathways mediated through integrins, RTKs, RAS, and TGF β (Kanteti et al, Oncotarget. 2016; 7(21):31586-601) and is also likely to suppress p53 expression to promote cell survival (Golubovskaya et al, International Review of Cytology. 2007; 263:103-153). Recent findings have demonstrated that integrins participate in the regulation of cancer stem-cell biology and are required for cancer progression, metastasis, and drug resistance via SRC/FAK signaling (Seguin et al, Trends Cell Biol. 2015; 25(4):234-40). Src has been identified as a key mediator of thyroid cancer pro-tumorigenic processes and a promising therapeutic target for thyroid cancer.
- Single-agent Src inhibition promotes a more invasive phenotype through an IL-1β>FAK>p130Cas>c-Jun >MMP signaling axis, and the combined inhibition of FAK and Src has the potential to block Src inhibitor-induced phenotype switch and resistance (Kessler et al, Oncogene. 2019; 38:2565-2579). Compensatory upregulation of the PI3K/AKT signaling pathway is a resistance mechanism in targeting KRAS mutation, which promotes cancer cell survival. FAK through phosphorylated Y397 directly interacts with the SH2 domain of p85, the regulatory subunit of PI3K to activate the PI3K pathway and suppress doxorubicin-induced apoptosis (van Nimwegen et al, Mol Pharmacol. 2006; 70(4):1330-1339). Src mediated phosphorylation of FAK at Y925 creates a docking site for GRB2 which activates the small GTP protein RAS and the downstream ERK2 (MAPK) (Kanteti et al, Oncotarget. 2016; 7(21):31586-601). Paxillin is a major component of focal adhesions that form a structural link between extracellular matrix and actin cytoskeleton. In cancer cells, its function is regulated through Src and FAK mediated phosphorylation. The dual inhibition of FAK and Src inhibitor was much more effective as compared to FAK inhibition alone as evidenced with increased cell detachment, inhibition of AKT/ERK1/2 and Src, and increased apoptosis (Golubovskaya et al, Molecular Cancer Research. 2003; 1(10):755-764). RhoA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. Pharmacologic inhibition of FAK in vivo downregulates p-AKT and does not trigger the emergence of PI3K/AKT-dependent compensatory mechanisms (Konstantinidou et al, Cancer Discov. 2013, 3(4):444-57). KRAS G12C inhibitor AMG-510 are less effective in KRAS G12C mutant colon cancer than in NSCLC (Govindan et al, Annals of Oncology, 2019, 30 (suppl 5): v159-v193. 10.1093/annonc/mdz244). It was reported that mutant KRAS activated p-STAT3 (Tyr705) in the absence of IL-6 secretion, and BCL-XL up-regulation by STAT3 contributes to mutant KRAS-mediated apoptosis resistance in colon cancer (Zaanan et al, J Biol Chem. 2015; 290(39):23838-49). Therefore, inhibition of JAK2 leading to modulation of STAT3 phosphorylation can be used to enable a synergistic apoptotic response in KRAS mutant colon cancer as well as other mutant KRAS cancers. In addition, Src and FAK regulate STAT3 which controls the expression angiogenetic factors such as VEGF (Niu et al Oncogene 2002, 21(13), 2000 - 8) as well as a range of cytokines (Cavalho et al Cancers 2019, 11(12), 2010). Taken together, Src, FAK, and JAK2 have key roles in mutant KRAS cancer by enabling angiogenesis in tumors, creating a pro-tumor immune response in the tumor microenvironment, and facilitating tumor cell signaling—both tumor cell intrinsic and extrinsic. In addition, the combined inhibition of Src, FAK, and JAK2 would have additional utility in diseases that have a pro-inflammatory component such as asthma, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and fibrosis.
- Overall, direct pharmacological targeting of activated RAS proteins has been challenging and has not yet led to successful treatments in the clinic although early antitumor activities have been observed with KRAS G12C inhibitors AMG510 and MRTX849 in
Phase 1 clinical studies in patients with KRAS G12C mutant cancers. The combination of a SRC/FAK/JAK2 inhibitor with an agent that inhibits KRAS G12C represents a novel therapeutic invention to maximize the antitumor activities and duration of response of an agent that inhibits KRAS G12C for the treatment of patients with the KRAS G12C mutation. - It has been discovered that the combination of an agent that inhibits KRAS G12C and one or more compounds that inhibit FAK, SRC and/or JAK2 provides a robust response in cancers harboring a KRAS G12C mutation.
- In one aspect, the disclosure provides a method for treating cancer in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of one or more compounds that inhibit FAK, SRC and/or JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C. In some embodiments, the host animal is a human patient. In some embodiments, the host animal is a laboratory animal such as a rodent.
- In another aspect, the disclosure provides a method for treating cancer in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C. In some embodiments, the host animal is a human patient. In some embodiments, the host animal is a laboratory animal such as a rodent.
- In another aspect, the disclosure provides one of more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- In another aspect, the disclosure provides a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- In another aspect, the disclosure provides use of one or more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., in the preparation of a medicament comprising a therapeutically effective amount of the compound, for treating cancer in a patient in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- In another aspect, the disclosure provides use of a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., in the preparation of a medicament comprising a therapeutically effective amount of the compound, for treating cancer in a patient in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- In another aspect, the disclosure provides a composition comprising one or more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., in a therapeutically effective amount, for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- In another aspect, the disclosure provides a composition comprising a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., in a therapeutically effective amount, for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- In another aspect, the disclosure provides a medicament comprising one or more compounds that inhibit FAK, SRC and/or JAK2, or a pharmaceutically acceptable salt thereof., combined with an agent that inhibits KRAS G12C, or a pharmaceutically acceptable salt thereof., in fixed or free combination.
- In another aspect, the disclosure provides a medicament comprising a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., combined with an agent that inhibits KRAS G12C, or a pharmaceutically acceptable salt thereof., in fixed or free combination.
- In another aspect, the disclosure provides a synergistic composition of one or more compounds that inhibit FAK, SRC and/or JAK2 and an agent that inhibits KRAS G12C, where the two components come into contact with each other at a locus.
- In another aspect, the disclosure provides a synergistic composition of a compound that inhibits FAK, SRC and JAK2 and an agent that inhibits KRAS G12C, where the two components come into contact with each other at a locus.
- In another aspect, the disclosure provides a synergistic composition of one or more compounds that inhibit FAK, SRC and/or JAK2, and an agent that inhibits KRAS G12C, where the two components come into contact with each other only in the human body.
- In another aspect, the disclosure provides a synergistic composition of a compound that inhibits FAK, SRC and JAK2, and an agent that inhibits KRAS G12C, where the two components come into contact with each other only in the human body. In some embodiments the compound that inhibits FAK, SRC and JAK2 is of the formula
- I
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, -CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OR7;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R10), wherein each R io is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
- In some embodiments of the above aspects, the compound that inhibits FAK, SRC and JAK2 is of the formula (referred to herein as Compound 1)
- or a pharmaceutically acceptable salt thereof.
- In some embodiments of the above aspects, the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule that inhibits KRAS G12C. In some embodiments of the above aspects, the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C. In some embodiments of the above aspects, the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA. In some embodiments of the above aspects, the at least one agent that inhibits KRAS G12C is a small molecule inhibitor.
- Additional embodiments, features, and advantages of the disclosure will be apparent from the following detailed description and through practice of the disclosure. The compounds of the present disclosure can be described as embodiments in any of the following enumerated clauses. It will be understood that any of the embodiments described herein can be used in connection with any other embodiments described herein to the extent that the embodiments do not contradict one another.
-
- 1. A method for treating cancer in a host animal, such as a human patient in need of such treatment, the method comprising the step of administering to the host animal a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- 2. The method of
clause 1, wherein the compound that inhibits FAK, SRC and JAK2 is of the formula I
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHCX6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R)1° , wherein each R′ ° is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
-
- 3. The method of
clause
- 3. The method of
- or a pharmaceutically acceptable salt thereof.
-
- 4. The method of
clause 1 to 3, wherein the cancer is selected from the group consisting of ALCL, non-small cell lung cancer, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CIVIL, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer, and lung cancer. - 5. The method of any one of
clauses 1 to 4, wherein the cancer is non-small cell lung cancer, metastatic non-small cell lung cancer, colorectal cancer, metastatic colorectal cancer, pancreatic cancer, metastatic pancreatic cancer, uterine cancer, or metastatic uterine cancer. - 6. The method of any one of
clauses 1 to 5, wherein the cancer is non-small cell lung cancer. - 7. The method of any one of
clauses 1 to 5, wherein the cancer is colorectal cancer. - 8. The method of any one of
clauses 1 to 7, wherein the compound that inhibits FAK, SRC, and JAK2 is administered at the same time as, before, or after the at least one agent that inhibits KRAS G12C. - 9. The method of any one of
clauses 1 to 8, wherein IL-6 secretion from the cancer is deceased. - 10. The method of any one of
clauses 1 to 9, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C. - 11. The method of any one of
clauses 1 to 10, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C. - 12. The method of clause 11, wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
- 13. The method of any one of
clauses 1 to 10, wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C. 14. The method of any one ofclauses 1 to 10 or 13, wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007. - 15. The method of any one of
clauses 1 to 10, 13 or 14, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof. - 16. The method of any one of
clauses 1 to 10, 13 or 14, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof. - 17. The method according to any one of the preceding clauses, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg.
- 18. The method according to any one of clauses 1 to 16, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg.
- 19. The method according to any one of the preceding clauses, wherein the host animal is a human patient in need of such treatment who has not received a prior treatment.
- 20. The method according to any one of
clauses 1 to 18, wherein the host animal is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies. - 21. The method according to any one of
clauses 1 to 18 or 20, wherein the host animal is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and developed an acquired resistance to the treatment, and/or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2. - 22. A compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- 23. The compound of
clause 22, wherein the compound that inhibits FAK, SRC and JAK2 is of the formula I
- 4. The method of
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R10), wherein each R io is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
-
- 24. The compound of
clause 22 or 23, wherein the compound that inhibits FAK, SRC and JAK2 is a compound of the formula
- 24. The compound of
- or a pharmaceutically acceptable salt thereof.
-
- 25. The compound of any one of
clauses 22 to 24, wherein the cancer is selected from the group consisting of ALCL, non-small cell lung cancer, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CML, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer, and lung cancer. - 26. The compound of any one of
clauses 22 to 25, wherein the cancer is non-small cell lung cancer, metastatic non-small cell lung cancer, colorectal cancer, metastatic colorectal cancer, pancreatic cancer, metastatic pancreatic cancer, uterine cancer, or metastatic uterine cancer. - 27. The compound of any one of
clauses 22 to 26, wherein the cancer is non-small cell lung cancer. - 28. The compound of any one of
clauses 22 to 26, wherein the cancer is colorectal cancer. - 29. The compound of any one of
clauses 22 to 28, wherein the method comprises administering the compound that inhibits FAK, SRC, and JAK2 is administered at the same time as, before, or after the at least one agent that inhibits KRAS G12C. - 30. The compound of any one of
clauses 22 to 29, wherein IL-6 secretion from the cancer is deceased. - 31. The compound of any one of
clauses 22 to 30, the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C. - 32. The compound of any one of
clauses 22 to 31, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C. - 33. The compound of clause 32, wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
- 34. The compound of any one of
clauses 22 to 31, wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C. - 35 The compound of any one of
clauses 22 to 31 or 34, wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007. - 36. The compound of any one of
clauses 22 to 31, 34, or 35, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof. - 37. The compound of any one of
clauses 22 to 31, 34, or 35, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof. - 38. The compound according to any one of
clauses 22 to 37, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg. - 39. The compound according to any one of clauses 22 to 37, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg.
- 40. The compound according to any one of
clauses 22 to 39, wherein the patient has not received a prior treatment. - 41. The compound according to any one of
clauses 22 to 39, wherein the patient has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies. - 42. The compound according to any one of
clauses 22 to 39, wherein the patient has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and developed an acquired resistance to the treatment, and/or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2. - 43. Use of a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., in the preparation of a medicament comprising a therapeutically effective amount of the compound, for treating cancer in a patient in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- 44. The use of clause 43, wherein the compound that inhibits FAK, SRC and JAK2 is of the formula I
- 25. The compound of any one of
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHCX6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R)1° , wherein each R′ ° is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
-
- 45. The use of clause 43 or 44, wherein the compound that inhibits FAK, SRC and JAK2 is a compound of the formula
- or a pharmaceutically acceptable salt thereof.
-
- 46. The use of any one of clauses 43 to 45, wherein the cancer is selected from the group consisting of ALCL, non-small cell lung cancer, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CML, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer, and lung cancer.
- 47. The use of any one of clauses 43 to 46, wherein the cancer is non-small cell lung cancer, metastatic non-small cell lung cancer, colorectal cancer, metastatic colorectal cancer, pancreatic cancer, metastatic pancreatic cancer, uterine cancer, or metastatic uterine cancer.
- 48. The use of any one of clauses 43 to 46, wherein the cancer is non-small cell lung cancer.
- 49. The use of any one of clauses 43 to 46, wherein the cancer is colorectal cancer.
- 50. The use of any one of clauses 43 to 49, wherein the medicament comprising the compound that inhibits FAK, SRC, and JAK2 is administered to the patient at the same time as, before, or after the at least one agent that inhibits KRAS G12C.
- 51. The use of any one of clauses 43 to 50, wherein IL-6 secretion from the cancer is deceased.
- 52. The use of any one of clauses 43 to 51, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C.
- 53. The use of any one of clauses 43 to 52, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C.
- 54. The use of any one of clauses 43 to 53, wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
- 55. The use of any one of clauses 43 to 52, wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C.
- 56. The use of any one of clauses 43 to 52 or 55, wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007.
- 57. The use of any one of clauses 43 to 52, 55, or 56, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.
- 58. The use of any one of clauses 43 to 52, 55, or 56, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.
- 59. The use of any one of clauses 43 to 58, wherein the compound that inhibits FAK, SRC and JAK2 is provided in the medicament in an amount of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is provided in an amount of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg.
- 60. The use of any one of clauses 43 to 58, wherein the compound that inhibits FAK, SRC and JAK2 is provided in the medicament in an amount of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is provided in an amount of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg.
- 61. The use of any one of clauses 43 to 60, wherein the patient has not received a prior treatment.
- 62. The use of any one of clauses 43 to 60, wherein the patient has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies.
- 63. The use of any one of clauses 43 to 60 or 62, wherein the patient has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and developed an acquired resistance to the treatment, and/or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2.
- 64. A composition comprising a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., in a therapeutically effective amount, for use in the treatment of cancer in a patient, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C.
- 65. The composition of clause 64, wherein the compound that inhibits FAK, SRC and JAK2 is of the formula I
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R10), wherein each R io is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
-
- 66. The composition of clause 64 or 65, wherein the compound that inhibits FAK, SRC and JAK2 is a compound of the formula
- or a pharmaceutically acceptable salt thereof.
-
- 67. The composition of any one of clauses 64 to 66, wherein the cancer is selected from the group consisting of ALCL, non-small cell lung cancer, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CML, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer, and lung cancer.
- 68. The composition of any one of clauses 64 to 67, wherein the cancer is non-small cell lung cancer, metastatic non-small cell lung cancer, colorectal cancer, metastatic colorectal cancer, pancreatic cancer, metastatic pancreatic cancer, uterine cancer, or metastatic uterine cancer.
- 69. The composition of any one of clauses 64 to 68, wherein the cancer is non-small cell lung cancer.
- 70. The composition of any one of clauses 64 to 68, wherein the cancer is colorectal cancer.
- 71. The composition of any one of clauses 64 to 70, wherein the composition comprising the compound that inhibits FAK, SRC, and JAK2 is administered to the patient at the same time as, before, or after the at least one agent that inhibits KRAS G12C.
- 72. The composition of any one of clauses 64 to 71, wherein IL-6 secretion from the cancer is deceased.
- 73. The composition of any one of clauses 64 to 72, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C.
- 74. The composition of any one of clauses 64 to 73, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C.
- 75. The composition of clause 74, wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
- 76. The composition of any one of clauses 64 to 73, wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C.
- 77. The composition of any one of clauses 64 to 73 or 76, wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007.
- 78. The composition of any one of clauses 64 to 73, 76, or 77, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.
- 79. The composition of any one of clauses 64 to 73, 76, or 77, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.
- 80. The composition of any one of clauses 64 to 79, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg.
- 81. The composition of any one of clauses 64 to 79, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg.
- 82. The composition of any one of clauses 64 to 81, wherein the host animal is a human patient in need of such treatment who has not received a prior treatment.
- 83. The composition of any one of clauses 64 to 81, wherein the host animal is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies.
- 84. The composition of any one of clauses 64 to 81 or 83, wherein the host animal is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and/or developed an acquired resistance to the treatment, or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2.
- 85. A medicament comprising a compound that inhibits FAK, SRC and JAK2, or a pharmaceutically acceptable salt thereof., combined with at least one agent that inhibits KRAS G12C, in fixed or free combination.
- 86. The medicament of clause 85, wherein the compound that inhibits FAK, SRC and JAK2 is of the formula I
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R)1° , wherein each R′ ° is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
-
- 87. The medicament of clause 85 or 86, wherein the compound that inhibits FAK, SRC and JAK2 is a compound of the formula
- or a pharmaceutically acceptable salt thereof.
-
- 88. The medicament of any one of clauses 85 to 87, wherein medicament provides a synergistic effect on a cancer selected from the group consisting of wherein the cancer is selected from the group consisting of ALCL, non-small cell lung cancer, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CML, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer, and lung cancer.
- 89. The medicament of any one of clauses 85 to 88, wherein the cancer is non-small cell lung cancer, metastatic non-small cell lung cancer, colorectal cancer, metastatic colorectal cancer, pancreatic cancer, metastatic pancreatic cancer, uterine cancer, or metastatic uterine cancer.
- 90. The medicament of any one of clauses 85 to 89, wherein the cancer is non-small cell lung cancer.
- 91. The medicament of any one of clauses 85 to 89, wherein the cancer is colorectal cancer.
- 92. The medicament of any one of clauses 85 to 89, wherein the cancer is pancreatic cancer.
- 93. The medicament of any one of clauses 85 to 92, wherein IL-6 secretion from the cancer is deceased.
- 94. The medicament of any one of clauses 85 to 93, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C.
- 95. The medicament of any one of clauses 85 to 94, wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C.
- 96. The medicament of clause 95, wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
- 97. The medicament of any one of clauses 85 to 95, wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C.
- 98. The medicament of any one of clauses 85 to 95 or 97, wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007.
- 99. The medicament of any one of clauses 85 to 95, 97 or 99, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.
- 100. The medicament of any one of clauses 85 to 95, 97 or 99, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.
- 101. The medicament of any one of clauses 85 to 100, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg.
- 102. The medicament of any one of clauses 85 to 100, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about mg/kg, or about 4.0 mg/kg.
- 103. A synergistic composition of a compound that inhibits FAK, SRC and JAK2 and an agent that inhibits KRAS G12C, where the two components come into contact with each other at a locus.
- 104. The synergistic composition of clause 103, wherein the compound that inhibits FAK, SRC and JAK2 is of the formula I
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R10), wherein each R io is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
-
- 105. The synergistic composition of clause 103 or 104, wherein the compound that inhibits FAK, SRC and JAK2 is a compound of the formula
- or a pharmaceutically acceptable salt thereof.
-
- 106. The synergistic composition of any one of clauses 103 to 105, wherein the locus is a cancer or a cancer cell.
- 107. The synergistic composition of any one of clauses 103 to 106, wherein the locus is a cancer selected from the group consisting of ALCL, non-small cell lung cancer, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CML, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer, and lung cancer.
- 108. The synergistic composition of clause 107, wherein the cancer is non-small cell lung cancer, metastatic non-small cell lung cancer, colorectal cancer, metastatic colorectal cancer, pancreatic cancer, metastatic pancreatic cancer, uterine cancer, or metastatic uterine cancer.
- 109. The synergistic composition of clause 107, wherein the cancer is non-small cell lung cancer.
- 110. The synergistic composition of clause 107, wherein the cancer is colorectal cancer.
- 111. The synergistic composition of clause 107, wherein the cancer is pancreatic cancer.
- 112. The synergistic composition of any one of clauses 106 to 111, wherein IL-6 secretion from the cancer is deceased.
- 113. The synergistic composition of any one of clauses 103 to 112, wherein the agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C.
- 114. The synergistic composition of any one of clauses 103 to 113, wherein the agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C.
- 115. The synergistic composition of clause 114, wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
- 116. The synergistic composition of any one of clauses 103 to 112, wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C.
- 117 The synergistic composition of any one of clauses 103 to 112 or 116, wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007.
- 118. The synergistic composition of any one of clauses 103 to 112, 116, or 117 wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.
- 119. The synergistic composition of any one of clauses 103 to 112, 116, or 117, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.
- 120. The synergistic composition of any one of clauses 103 to 119, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg.
- 121. The synergistic composition of any one of clauses 103 to 119, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg.
- 122. The synergistic composition of any one of clauses 106 to 119, wherein the cancer or cancer cell has previously been contacted with at least one prior treatment of one or more chemotherapeutic agents or immunotherapies.
- 123. The synergistic composition of any one of clauses 106 to 119, wherein the cancer or cancer cell has previously been contacted with at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and/or developed an acquired resistance to the treatment, or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2.
- 124. A synergistic composition of a compound that inhibits FAK, SRC and JAK2 and an agent that inhibits KRAS G12C, where the two components come into contact with each other only in the human body.
- 125. The synergistic composition of clause 124, wherein the compound that inhibits FAK, SRC and JAK2 is of the formula I
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R)1° , wherein each R′ ° is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
-
- 126. The synergistic composition of clause 124 or 125, wherein the compound that inhibits FAK, SRC and JAK2 is a compound of the formula
- or a pharmaceutically acceptable salt thereof.
-
- 127. The synergistic composition of any one of clauses 124 to 126, wherein the agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C.
- 128. The synergistic composition of any one of clauses 124 to 127, wherein the agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C.
- 129. The synergistic composition of clause 128, wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
- 130. The synergistic composition of any one of clauses 124 to 128, wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C.
- 131. The synergistic composition of any one of clauses 124 to 128 or 130, wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007.
- 132. The synergistic composition of any one of clauses 124 to 128, 130 or 131, wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.
- 133. The synergistic composition of any one of clauses 124 to 128, 130 or 131, wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.
- 134. The synergistic composition of any one of clauses 124 to 133, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg.
- 135. The synergistic composition of any one of clauses 124 to 133, wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg.
- 136. The synergistic composition of any one of clauses 124 to 135, wherein the human body has not received a prior treatment.
- 137. The synergistic composition of any one of clauses 124 to 135, wherein the human body has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies.
- 138. The synergistic composition of any one of clauses 124 to 135 or 137, wherein the host animal is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and/or developed an acquired resistance to the treatment, or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2.
-
FIG. 1 a shows the level of caspase-3/7 activated by Compound 1 (1 μM), AMG-510 (50 nM) and Compound 1 (1 μM)+AMG510 (50 nM) in H358 cells with KRAS G12C mutation after 24 hrs. -
FIG. 1B shows the level of caspase-3/7 activated by Compound 1 (1 μM), AMG-510 (50 nM) and Compound 1 (1 μM)+AMG510 (50 nM) in H358 cells with KRAS G12C mutation after 48 hrs. -
FIG. 1 c shows the level of caspase-3/7 activated by Compound 1 (1 μM), AMG-510 (50 nM) and Compound 1 (1 μM)+AMG510 (50 nM) in H2122 cells with KRAS G12C mutation after 24 hrs. -
FIG. 1 d shows the level of caspase-3/7 activated by Compound 1 (1 μM), AMG-510 (50 nM) and Compound 1 (1 μM)+AMG510 (50 nM) in H2122 cells with KRAS G12C mutation after 48 hrs. -
FIG. 1 e shows the level of caspase-3/7 activated by Compound 1 (1 μM), AMG-510 (50 nM) and Compound 1 (1 μM)+AMG510 (50 nM) in H1373 cells with KRAS G12C mutation after 24 hrs. - FIG. if shows the level of caspase-3/7 activated by Compound 1 (1 μM), AMG-510 (50 nM) and Compound 1 (1 μM)+AMG510 (50 nM) in H1373 cells with KRAS G12C mutation after 48 hrs.
-
FIG. 2 a is a chart showing the 2D dose response matrix after treatment of H2122 cells with acompound 1 and KRAS inhibitor AMG-510 at various concentrations from 0 nM to 3000 nM ofCompound 1, and from 0 nM to 10000 nM KRAS inhibitor AMG-510. -
FIG. 2 b is a chart showing the 2D dose response matrix after treatment of H2122 cells with acompound 1 and KRAS inhibitor MRTX849 at various concentrations from 0 nM to 3000 nM ofCompound 1, and from 0 nM to 10000 nM KRAS inhibitor MRTX849. -
FIG. 3 a is a graph showing decreased IL-6 secretion in H358 and H2122 NSCLC cell lines treated for 48 h with a combination ofCompound 1 with AMG-510. (a) Control; (b) AMG-510; (c)Compound 1; (d)Compound 1+AMG-510. -
FIG. 3 b is a chart showing decreased secretion of IL-6, MCP-1, TGF-01, PDGF-BB, and MIP-3-alpha in H358 cells treated with the combination ofCompound 1 and AMG-510 for 48 h. (a) Control; (b) AMG-510; (c)Compound 1; (d)Compound 1+AMG-510. -
FIG. 3 c is a chart showing decreased secretion of IL-6, IGFBP-4 and NAP-2 in H2122 cells treated with the combination ofCompound 1 and AMG-510 for 48 h. (a) Control; (b) AMG-510; (c)Compound 1; (d)Compound 1+AMG-510. -
FIG. 3 d is a chart showing decreased secretion of IL-6,GRO, GRO-alpha, IL-10, osteopontin, and osteoprotegerin in H358 cells treated with the combination ofCompound 1 and AMG-510 for 24 h. (a) Control; (b) AMG-510; (c)Compound 1; (d)Compound 1+AMG-510. -
FIG. 3 e is a graph showing decreased IL-6 secretion in H2122 NSCLC cell lines treated for 48 h with a combination ofCompound 1 with MRTX849. (a) Control; (b) MRTX849; (c)Compound 1; (d)Compound 1+MRTX849. -
FIG. 3 f is an ELISA assay showing decreased IL-6 secretion in H2122 NSCLC cell lines treated for 48 h with a combination ofCompound 1 with MRTX849. -
FIG. 3 g is a graph showing the effect ofCompound 1 alone, MRTX849 alone, and the combination ofCompound 1 and MRTX849 on IL6 mRNA expression fromH2122 cells 24 and 48 hrs after treatment. -
FIG. 4 a is a chart showing the antitumor effect ofCompound 1 in combination with AMG-510 in H358 cell-derived xenograft tumors harboring a KRAS G12C mutation. (●) Control; (▾) Compound 1 (15 mg/kg BID); (+) AMG-510 (10 mg/kg QD); (●) Compound 1 (15 mg/kg BID) plus AMG-510 (10 mg/kg QD). -
FIG. 4 b is a chart showing the body weight of mice bearing H358 cell-derived tumors harboring a KRAS G12C mutation when treated withCompound 1 in combination with AMG-510. (●) Control; (▾) Compound 1 (15 mg/kg BID); (♦) AMG-510 (10 mg/kg QD); (●) Compound 1 (15 mg/kg BID) plus AMG-510 (10 mg/kg QD). -
FIG. 5 a is a chart showing the antitumor effect ofCompound 1 in combination with AMG-510 in LU11693 PDX model harboring a KRAS G12C mutation. The dose of AMG-510 was reduced to 30 mg/kg QD after 14 days of treatment. Two mice in the combination treatment group terminated onday 13. (●) Control; (▪) Compound 1 (15 mg/kg BID); (▴) AMG-510 (100 mg/kg QD); (▾) Compound 1 (15 mg/kg BID) plus AMG-510 (100 mg/kg QD). -
FIG. 5 b is a chart showing the body weight of mice bearing LU11693 PDX harboring a KRAS G12C mutation when treated withCompound 1 in combination with AMG-510. The dose of AMG-510 was reduced to 30 mg/kg QD after 14 days of treatment. Two mice in the combination treatment group terminated onday 13. (●) Control; (▪) Compound 1 (15 mg/kg BID); (▴) AMG-510 (100 mg/kg QD); (▾) Compound 1 (15 mg/kg BID) plus AMG-510 (100 mg/kg QD). -
FIG. 6 a is a chart showing the effect ofCompound 1 in combination with AMG-510 on survival in H2122 cell-derived xenograft tumor model harboring a KRAS G12C mutation. The dose level of AMG-510 was at 10 mg/kg QD. () Control; () Compound 1 (15 mg/kg BID); () AMG-510 (10 mg/kg QD); () Compound 1 (15 mg/kg BID) plus AMG-510 (10 mg/kg QD). -
FIG. 6 b is a chart showing the effect ofCompound 1 in combination with AMG-510 on survival in H2122 cell-derived xenograft tumor model harboring a KRAS G12C mutation. The dose level of AMG-510 was at 30 mg/kg QD. () Control; () Compound 1 (15 mg/kg BID); () AMG-510 (30 mg/kg QD); () Compound 1 (15 mg/kg BID) plus AMG-510 (30 mg/kg QD). - Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. All patents, applications, published applications and other publications referred to herein are incorporated by reference in their entireties. If a definition set forth in this section is contrary to or otherwise inconsistent with a definition set forth in a patent, application, or other publication that is herein incorporated by reference, the definition set forth in this section prevails over the definition incorporated herein by reference.
- As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.
- As used herein, the terms “including,” “containing,” and “comprising” are used in their open, non-limiting sense.
- To provide a more concise description, some of the quantitative expressions given herein are not qualified with the term “about”. It is understood that, whether the term “about” is used explicitly or not, every quantity given herein is meant to refer to the actual given value, and it is also meant to refer to the approximation to such given value that would reasonably be inferred based on the ordinary skill in the art, including equivalents and approximations due to the experimental and/or measurement conditions for such given value. Whenever a yield is given as a percentage, such yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be obtained under the particular stoichiometric conditions. Concentrations that are given as percentages refer to mass ratios, unless indicated differently.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.
- Except as otherwise noted, the methods and techniques of the present embodiments are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Loudon, Organic Chemistry, Fourth Edition, New York: Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fifth Edition, Wiley-Interscience, 2001.
- Chemical nomenclature for compounds described herein has generally been derived using the commercially-available ACD/Name 2014 (ACD/Labs) or ChemBioDraw Ultra 13.0 (Perkin Elmer).
- It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. All combinations of the embodiments pertaining to the chemical groups represented by the variables are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed, to the extent that such combinations embrace compounds that are stable compounds (i.e., compounds that can be isolated, characterized, and tested for biological activity). In addition, all subcombinations of the chemical groups listed in the embodiments describing such variables are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination of chemical groups was individually and explicitly disclosed herein.
- The methods described herein are used to treat a “host animal” with cancer in need of such treatment. In one embodiment, the methods described herein can be used for both human clinical medicine and veterinary applications. Thus, a “host animal” can be administered the combinations described herein, and the host animal can be human (e.g., a human patient, a.k.a. a patient) or, in the case of veterinary applications, can be a laboratory, agricultural, or domestic animal. In one aspect, the host animal can be a human, or a laboratory animal such as a rodent (e.g., mice, rats, etc.), and the like.
- As used herein, the term “disease” includes, but is not limited to, cancer, pain, inflammatory diseases, such as allergy, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease (e.g. ulcerative colitis), pre-perfusion injury, transplant rejection, psoriasis, and rheumatoid arthritis; polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
- As used herein, the term “cancer” includes, but is not limited to, ALCL, lung cancer, such as non-small cell lung cancer (NSCLC), including adenocarcinoma, lung squamous cell carcinoma, large cell carcinoma, and large cell neuroendocrine tumors, small cell lung cancer (SCLC), neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, such as luminal A, luminal B, triple negative breast cancer, triple positive breast cancer, HER2+, and the like, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, thyroid cancer, such as anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, gastric cancer, such as gastric adenocarcinoma, colorectal cancer (CRC), inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid papillary cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, skin cancer, such as skin cutaneous melanoma, head and neck squamous cell carcinoma (HNSCC), pediatric glioma CML, prostate cancer, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, uterine cancer, such as serous and clear cell endometrial cancer, endometrial cancer, and the like, oral cancer, endocrine cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, and stomach cancer. It will be appreciated that the term “cancer” includes both primary cancers or primary tumors and metastatic cancers or metastatic tumors, and includes all stages of cancer as known in the art. For example, metastatic NSCLC, metastatic CRC, metastatic pancreatic cancer, metastatic colorectal carcinoma, metastatic HNSCC, metastatic uterine cancer, and the like. It will be appreciated that the term “cancer” includes cancers that involve the upregulation of certain genes or genetic mutations in certain genes that can lead to disease progression, such as small GTPases (e.g. KRAS and the like) and receptor tyrosine kinases such as EGFR, and the like.
- As used herein, the term “agent that inhibits KRAS G12C” includes, but is not limited to, any compound or agent known in the art to selectively inhibit the KRAS G12C gene or selectively inhibit the protein encoded by the KRAS G12C gene, referred to herein as K-Ras G12C, that is involved in the RAS/MAPK signaling pathway, where the K-Ras protein product of the KRAS gene has the missense mutation G12C. The terms KRAS gene, K-Ras, and RAS/MAPK signaling pathway will be known and understood by one of skill in the art. It will be appreciated that the KRAS G12C mutation encodes a glycine to cysteine mutation at
position 12 of the K-Ras protein (a.k.a. K-Ras G12C). It will further be appreciated that the production of a K-Ras G12C protein as a gene product of the KRAS G12C gene can be the result of a coding sequence mutation, e.g. guanine to thymine substitution, atposition 34 of the coding sequence. It will be further appreciated that the agent that inhibits KRAS G12C can be any agent known in the art that selectively targets the KRAS G12C gene, and includes those agents, such as siRNA, oligonucleotides, ribonucleic acids, and the like, that selectively inhibit or are capable of otherwise selectively interfering with the transcription (and/or translation) of the KRAS G12C gene (or its corresponding messenger RNA) to the K-Ras G12C protein. It will further be appreciated that an agent that inhibits KRAS G12C can be an agent capable of selectively inhibiting or otherwise selectively interfering with KRAS G12C transcription and/or translation of the corresponding messenger RNA can be a biological agent, such as a siRNA, oligonucleotide, ribonucleic acid, and the like. Alternatively, it will be appreciated that an agent that inhibits KRAS G12C can be an agent that selectively inhibits the protein encoded by the KRAS G12C gene having a coding sequence that produces a K-Ras G12C protein (e.g. a guanine to thymine substitution, atposition 34 of the KRAS coding sequence) can be a biological agent, such as an antibody (e.g. a monoclonal antibody or mAb), a small molecule drug/inhibitor (e.g. small molecule inhibitor of KRAS G12C), or a targeted agent. Examples of “an agent that inhibits KRAS G12C” can include, but are not limited to AMG-510, MRTX849, JNJ-74699157 (a.k.a. ARS-3248), ARS-1620, MRTX1257, RM-007 or ADT-007. In some embodiments, the agent that inhibits KRAS G12C is a compound described in United States Patent Publication US20180334454, incorporated herein by reference for exemplary agents that inhibit KRAS G12C (a.k.a. exemplary small molecule inhibitor of KRAS G12C) and their preparation. In some embodiments, the agent that inhibits KRAS G12C is AMG510 having the formula - or a pharmaceutically acceptable salt thereof.
- In some embodiments, the agent that inhibits KRAS G12C is a compound described in United States Patent Publications US20190270743 and US20190144444, incorporated herein by reference for exemplary agents that inhibit KRAS G12C (a.k.a. exemplary small molecule inhibitor of KRAS G12C) and their preparation. In some embodiments, the agent that inhibits KRAS G12C is MRTX849 having the formula
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, the agent that inhibits KRAS G12C is AMG-510, MRTX849, or ARS-1620, or a pharmaceutically acceptable salt thereof.
- As used herein, the term “alkyl” includes a chain of carbon atoms, which is optionally branched and contains from 1 to 20 carbon atoms. It is to be further understood that in certain embodiments, alkyl may be advantageously of limited length, including C1-C12, C1-C10, C1-C9, C1-C8, C1-C7, C1-C6, and C1-C4, Illustratively, such particularly limited length alkyl groups, including C1-C8, C1-C7, C1-C6, and C1-C4, and the like may be referred to as “lower alkyl.” Illustrative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl, hexyl, heptyl, octyl, and the like. Alkyl may be substituted or unsubstituted. Typical substituent groups include cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, oxo, (═O), thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, nitro, and amino, or as described in the various embodiments provided herein. It will be understood that “alkyl” may be combined with other groups, such as those provided above, to form a functionalized alkyl. By way of example, the combination of an “alkyl” group, as described herein, with a “carboxy” group may be referred to as a “carboxyalkyl” group. Other non-limiting examples include hydroxyalkyl, aminoalkyl, and the like.
- As used herein, the term “alkenyl” includes a chain of carbon atoms, which is optionally branched, and contains from 2 to 20 carbon atoms, and also includes at least one carbon-carbon double bond (i.e. C═C). It will be understood that in certain embodiments, alkenyl may be advantageously of limited length, including C2-C12, C2-C9, C2-C8, C2-C7, C2-C6, and C2-C4. Illustratively, such particularly limited length alkenyl groups, including C2-C8, C2-C7, C2-C6, and C2-C4 may be referred to as lower alkenyl. Alkenyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein. Illustrative alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2-, or 3-butenyl, and the like.
- As used herein, the term “alkynyl” includes a chain of carbon atoms, which is optionally branched, and contains from 2 to 20 carbon atoms, and also includes at least one carbon-carbon triple bond (i.e. CC). It will be understood that in certain embodiments, alkynyl may each be advantageously of limited length, including C2-C12, C2-C9, C2-C8, C2-C7, C2-C6, and C2-C4. Illustratively, such particularly limited length alkynyl groups, including C2-C8, C2-C7, C2-C6, and C2-C4 may be referred to as lower alkynyl. Alkenyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein. Illustrative alkenyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1—, 2—, or 3-butynyl, and the like.
- As used herein, the term “aryl” refers to an all-carbon monocyclic or fused-ring polycyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-electron system. It will be understood that in certain embodiments, aryl may be advantageously of limited size such as C6-C10 aryl. Illustrative aryl groups include, but are not limited to, phenyl, naphthalenyl and anthracenyl. The aryl group may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein.
- As used herein, the term “cycloalkyl” refers to a 3 to 15 member all-carbon monocyclic ring, including an all-carbon 5-member/6-member or 6-member/6-member fused bicyclic ring, or a multicyclic fused ring (a “fused” ring system means that each ring in the system shares an adjacent pair of carbon atoms with each other ring in the system) group, where one or more of the rings may contain one or more double bonds but the cycloalkyl does not contain a completely conjugated pi-electron system. It will be understood that in certain embodiments, cycloalkyl may be advantageously of limited size such as C3-C13, C3-C9, C3-C6 and C4-C6. Cycloalkyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein. Illustrative cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, adamantyl, norbornyl, norbornenyl, 9H-fluoren-9-yl, and the like. Illustrative examples of cycloalkyl groups shown in graphical representations include the following entities, in the form of properly bonded moieties:
- As used herein, the term “heterocycloalkyl” refers to a monocyclic or fused ring group having in the ring(s) from 3 to 12 ring atoms, in which at least one ring atom is a heteroatom, such as nitrogen, oxygen or sulfur, the remaining ring atoms being carbon atoms. Heterocycloalkyl may optionally contain 1, 2, 3 or 4 heteroatoms. Heterocycloalkyl may also have one of more double bonds, including double bonds to nitrogen (e.g. C=N or N=N) but does not contain a completely conjugated pi-electron system. It will be understood that in certain embodiments, heterocycloalkyl may be advantageously of limited size such as 3- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkyl, and the like. Heterocycloalkyl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein. Illustrative heterocycloalkyl groups include, but are not limited to, oxiranyl, thianaryl, azetidinyl, oxetanyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, piperazinyl, oxepanyl, 3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl, 1,2,3,4-tetrahydropyridinyl, and the like. Illustrative examples of heterocycloalkyl groups shown in graphical representations include the following entities, in the form of properly bonded moieties:
- As used herein, the term “heteroaryl” refers to a monocyclic or fused ring group of 5 to 12 ring atoms containing one, two, three or four ring heteroatoms selected from nitrogen, oxygen and sulfur, the remaining ring atoms being carbon atoms, and also having a completely conjugated pi-electron system. It will be understood that in certain embodiments, heteroaryl may be advantageously of limited size such as 3- to 7-membered heteroaryl, 5- to 7-membered heteroaryl, and the like. Heteroaryl may be unsubstituted, or substituted as described for alkyl or as described in the various embodiments provided herein. Illustrative heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, purinyl, tetrazolyl, triazinyl, pyrazinyl, tetrazinyl, quinazolinyl, quinoxalinyl, thienyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, benzisoxazolyl, benzisothiazolyl and carbazoloyl, and the like. Illustrative examples of heteroaryl groups shown in graphical representations, include the following entities, in the form of properly bonded moieties:
- As used herein, “hydroxy” or ““hydroxyl” refers to an —OH group.
- As used herein, “alkoxy” refers to both an —O-(alkyl) or an —O-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cycl op entyl oxy, cyclohexyloxy, and the like.
- As used herein, “aryloxy” refers to an —O-aryl or an —O-heteroaryl group. Representative examples include, but are not limited to, phenoxy, pyridinyloxy, furanyloxy, thienyloxy, pyrimidinyloxy, pyrazinyloxy, and the like.
- As used herein, “mercapto” refers to an —SH group.
- As used herein, “alkylthio” refers to an —S-(alkyl) or an —S-(unsubstituted cycloalkyl) group. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, and the like.
- As used herein, “arylthio” refers toh an —S-aryl or an —S-heteroaryl group. Representative examples include, but are not limited to, phenylthio, pyridinylthio, furanylthio, thienylthio, pyrimidinylthio, and the like.
- As used herein, “halo” or “halogen” refers to fluorine, chlorine, bromine or iodine.
- As used herein, “cyano” refers to a —CN group.
- The term “oxo” represents a carbonyl oxygen. For example, a cyclopentyl substituted with oxo is cyclopentanone.
- As used herein, “bond” refers to a covalent bond.
- The term “substituted” means that the specified group or moiety bears one or more substituents. The term “unsubstituted” means that the specified group bears no substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In some embodiments, “substituted” means that the specified group or moiety bears one, two, or three substituents. In other embodiments, “substituted” means that the specified group or moiety bears one or two substituents. In still other embodiments, “substituted” means the specified group or moiety bears one substituent.
- As used herein, “optional” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl is independently optionally substituted by C1-C6 alkyl” means that an alkyl may be but need not be present on any of the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl by replacement of a hydrogen atom for each alkyl group, and the description includes situations where the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl is substituted with an alkyl group and situations where the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl is not substituted with the alkyl group.
- As used herein, “independently” means that the subsequently described event or circumstance is to be read on its own relative to other similar events or circumstances. For example, in a circumstance where several equivalent hydrogen groups are optionally substituted by another group described in the circumstance, the use of “independently optionally” means that each instance of a hydrogen atom on the group may be substituted by another group, where the groups replacing each of the hydrogen atoms may be the same or different. Or for example, where multiple groups exist all of which can be selected from a set of possibilities, the use of “independently” means that each of the groups can be selected from the set of possibilities separate from any other group, and the groups selected in the circumstance may be the same or different.
- As used herein, the term “pharmaceutically acceptable salt” refers to those salts which counter ions which may be used in pharmaceuticals. See, generally, S. M. Berge, et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977, 66, 1-19. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of subjects without undue toxicity, irritation, or allergic response. A compound described herein may possess a sufficiently acidic group, a sufficiently basic group, both types of functional groups, or more than one of each type, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. Such salts include:
-
- (1) acid addition salts, which can be obtained by reaction of the free base of the parent compound with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perchloric acid and the like, or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methane sulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid or malonic acid and the like; or
- (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, trimethamine, N-methylglucamine, and the like.
- Pharmaceutically acceptable salts are well known to those skilled in the art, and any such pharmaceutically acceptable salt may be contemplated in connection with the embodiments described herein. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, methylsulfonates, propylsulfonates, besylates, xylenesulfonates, naphthalene-l-sulfonates, naphthalene-2-sulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycolates, tartrates, and mandelates. Lists of other suitable pharmaceutically acceptable salts are found in Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company, Easton, Pa., 1985.
- Any formula depicted herein is intended to represent a compound of that structural formula as well as certain variations or forms. For example, a formula given herein is intended to include a racemic form, or one or more enantiomeric, diastereomeric, or geometric isomers, or a mixture thereof. Additionally, any formula given herein is intended to refer also to a hydrate, solvate, or polymorph of such a compound, or a mixture thereof. For example, it will be appreciated that compounds depicted by a structural formula containing the symbol “” include both stereoisomers for the carbon atom to which the symbol “” is attached, specifically both the bonds “” and “” are encompassed by the meaning of “”. For example, in some exemplary embodiments, certain compounds provided herein can be described by the formula
- which formula will be understood to encompass compounds having all stereochemical configurations at the relevant carbon atoms, including
- In some embodiments, the methods described herein relate to the treatment of cancer comprising administering to a patient in need of treatment a therapeutically effective amount of one or more compounds that inhibit FAK, SRC and/or JAK2 in combination with an agent that inhibits KRAS G12C. In some embodiments, the methods described herein relate to the treatment of cancer comprising administering to a patient in need of treatment a therapeutically effective amount of a compound that inhibits FAK, SRC and JAK2 in combination with an agent that inhibits KRAS G12C. It will be appreciated that an inhibitor is any substance that reduces or suppresses the activity of another substance, such as a cell surface receptor (i.e. a receptor tyrosine kinase), or a kinase (i.e. a non-receptor tyrosine kinase), or the transcription and/or translation of a gene. It will be appreciated that “a compound that inhibits FAK, SRC and JAK2” is a compound that has affinity for all three of the biological targets FAK, SRC and JAK2.
- It has been discovered that certain compounds described herein have been surprisingly shown to be inhibitors of FAK, SRC and JAK2, and can be used in combination with an agent that inhibits KRAS G12C to treat cancer in a patient in need of such treatment. In some embodiments, the combination of one or more compounds that inhibit FAK, SRC and/or JAK2 with an agent that inhibits KRAS G12C can provide a synergistic response in a patient in need of treatment for cancer. In some embodiments, the combination of a compound that inhibits FAK, SRC and JAK2 with an agent that inhibits KRAS G12C can provide a synergistic response in a patient in need of treatment for cancer. In some embodiments, methods for treating cancer comprising administering a combination of a therapeutically effective amount of a compound that inhibits FAK, SRC and JAK2 and a therapeutically effective amount of an agent that inhibits KRAS G12C. In some embodiments, the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are co-formulated. In some embodiments, the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are administered at the same time. In some embodiments, the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are individually formulated, and administered at the same time. In some embodiments, the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C are individually formulated, and administered in sequence. In some embodiments, the sequential administration of the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C can be accomplished with the compound that inhibits FAK, SRC and JAK2 administered first, and the agent that inhibits KRAS G12C administered second. In some embodiments, the sequential administration of the compound that inhibits FAK, SRC and JAK2 and the agent that inhibits KRAS G12C can be accomplished with agent that inhibits KRAS G12C administered first, and the compound that inhibits FAK, SRC and JAK2 administered second.
- In some embodiments, the compound that inhibits FAK, SRC and JAK2 is of the formula I
- wherein
- M is CR5 or N;
- X1 and X2 are independently —C(R7)(R8)—, —S—, —S(O)—, —S(O)2—, —O— or —N(R9)—;
- each R1 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R2 and R3 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C6-C10 aryl, —C(O)OR7 or —C(O)NR7R8; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl and C6-C10 aryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- R4 and R5 are each independently H, fluoro, chloro, bromo, C1-C6 alkyl, —OH, —CN, —OC1-C6 alkyl, —NHC1-C6 alkyl, —N(C1-C6 alkyl)2 or —CF3;
- R6 is H, C1-C6 alkyl or 3-to 7-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl or 3- to 7-membered heterocycloalkyl is independently optionally substituted by halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —CO2H, —CO2C1-C6 alkyl, —CONH2, —CONH(C1-C6 alkyl), —CON(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3- to 7-membered heterocycloalkyl;
- each R7 and R8 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl or 5- to 7-membered heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —OH, —CN, —OC1-C6 alkyl, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)C1-C6 alkyl, —N(C1-C6 alkyl)C(O)C1-C6 alkyl, —NHC(O)NH2, —NHC(O)NHC1-C6 alkyl, —N(C1-C6 alkyl)C(O)NH2, —N(C1-C6 alkyl)C(O)NHC1-C6 alkyl, —NHC(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)C(O)N(C1-C6 alkyl)2, —NHC(O)OC1-C6 alkyl, —N(C1-C6 alkyl)C(O)OC1-C6 alkyl, —NHS(O)(C1-C6 alkyl), —NHS(O)2(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2(C1-C6 alkyl), —NHS(O)NH2, NHS(O)2NH2, —N(C1-C6 alkyl)S(O)NH2, —N(C1-C6 alkyl)S(O)2NH2, —NHS(O)NH(C1-C6 alkyl), —NHS(O)2NH(C1-C6 alkyl), —NHS(O)N(C1-C6 alkyl)2, —NHS(O)2N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)2NH(C1-C6 alkyl), —N(C1-C6 alkyl)S(O)N(C1-C6 alkyl)2, —N(C1-C6 alkyl)S(O)2N(C1-C6 alkyl)2, —CO2H, —C(O)OC1-C6 alkyl, —C(O)NH2, —C(O)NH(C1-C6 alkyl), —C(O)N(C1-C6 alkyl)2, —SC1-C6 alkyl, —S(O)C1-C6 alkyl, —S(O)2C1-C6 alkyl, —S(O)NH(C1-C6 alkyl), —S(O)2NH(C1-C6 alkyl), —S(O)N(C1-C6 alkyl)2, —S(O)2N(C1-C6 alkyl)2, —P(C1-C6 alkyl)2, —P(O)(C1-C6 alkyl)2, C3-C6 cycloalkyl, or 3-to 7-membered heterocycloalkyl;
- each R9 is independently H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3-to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl; wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl or —OW;
- each Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is independently N, NH, or C(R10), wherein each R io is independently H, deuterium, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —OH, —NH2, —NH(C1-C6 alkyl), —NH(phenyl), —NH(heteroaryl), —CN, or —CF3, and
- provided that at least one of Z1, Z2, Z3, Z4, Z5, Z6 or Z7 is N or NH;
- or a pharmaceutically acceptable salt thereof.
- In some embodiments, R1 is H or C1-C6 alkyl. In some embodiments, R1 is H or methyl. In some embodiments, one of R1 is H and the other of R1 is methyl. In some embodiments, R2 is H. In some embodiments, R2 is C1-C6 alkyl. In some embodiments, one of R2 is H and the other of R2 is methyl. In some embodiments, X i is —NR9—. In some embodiments, R9 is H. In some embodiments, X1 is CHR7. In some embodiments, R7 is H. In some embodiments, X2 is —O—. In some embodiments, R6 is H. In some embodiments, R4 is F. In some embodiments, M is CR5, and R5 is H.
- Macrocyclic compounds that have been shown herein to be potent small-molecule multi-target kinase inhibitors showing activity against FAK, SRC and JAK2 include, but are not limited to, (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one (also herein referred to as “
Compound 1”), represented by the formula -
Compound 1 has properties, including anti-tumor properties, which are pharmacologically mediated through inhibition of receptor and non-receptor tyrosine kinases.Compound 1 is disclosed in International Patent Publication WO2015/112806, which is incorporated herein by reference for the preparation ofCompound 1. - In some embodiments of the above aspects, the compound that inhibits FAK, SRC and JAK2 is of the formula
- or a pharmaceutically acceptable salt thereof.
- It will be appreciated that the cancer can be any cancer that may be mediated by or associated with KRAS G12C, or the upregulation of KRAS G12C, including but not limited to, ALCL, NSCLC, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CML, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer and lung cancer.
- In some embodiments, the present disclosure provides methods of treating disease in a patient that has received no prior treatment. In some embodiments, the present disclosure provides methods of treating disease in a patient that has received a prior treatment with one or more therapeutic agents. In some embodiments, the patient has been previously treated with one or more chemotherapeutic agents. In still other embodiments, the patent has been previously treated with one or more chemotherapeutic agents or immunotherapies and developed an acquired resistance to the treatment. In still other embodiments, the patent has been previously treated with one or more chemotherapeutic agents or immunotherapies and developed bypass resistance to the treatment. In still other embodiments, the patent has been previously treated with one or more chemotherapeutic agents or immunotherapies and developed bypass resistance to the treatment regulated by FAK, SRC or JAK2, and/or FAK.
- Other chemotherapeutic agents which the patient may be been treated with prior to treatment with one or more of the compounds or biological agents described herein include but are not limited to kinase inhibitors, adrenocorticoids and corticosteroids, alkylating agents, peptide and peptidomimetic signal transduction inhibitors, antiandrogens, antiestrogens, androgens, aclamycin and aclamycin derivatives, estrogens, antimetabolites, platinum compounds, amanitins, plant alkaloids, mitomycins, discodermolides, microtubule inhibitors, epothilones, inflammatory and proinflammatory agents, purine analogs, pyrimidine analogs, camptothecins, dolastatins, and or immunotherapies. In some embodiments, the patient has been administered a prior treatment for NSCLC, such as pembrolizumab, platinum, platinum doublet, pemetrexed, carboplatin, paclitaxel, bevacizumab, atezolizumab, abraxane, and combinations thereof. In some embodiments, the patient has been administered a prior treatment for NSCLC cancer that is the standard of care using one or more agents selected from the group consisting of pembrolizumab, platinum, platinum doublet, pemetrexed, carboplatin, paclitaxel, bevacizumab, atezolizumab, and abraxane.
- In some embodiments, the patient has been administered a prior treatment for colorectal cancer, such as fluorouracil (5-FU), leucovorin, irinotecan, oxaliplatin, capecitabine, bevacizumab, cetuximab, panitumumab, ziv-aflibercept, ramucirumab, pemborlizumab, nivolumab, ipilimumab, encorafenib, binimetinib, and combinations thereof. In some embodiments, the patient has been administered a prior treatment for colorectal cancer that is the standard of care using one or more agents selected from the group consisting of FOLFOX (i.e. 5-FU+leucovorin+irinotecan)+/−bevacizumab, panitumumab or cetuximab, CAPEOX (i.e. oxaliplatin+capecitabine)+/−bevacizumab, FOLFIRI (i.e. 5-FU+leucovorin+irinotecan)+/−bevacizumab, cetuximab, panitumumab, ziv-aflibercept or ramucirumab, FOLFOXIRI (i.e. irinotecan, oxaliplatin, leucovorin, 5-FU), irinotecan+cetuximab, panitumumab, or amucirumab, pemborlizumab, nivolumab, nivolumab+ipilimumab, encorafenib, and binimetinib.
- In some embodiments, the patient has been administered a prior treatment for pancreatic cancer, such as fluorouracil (5-FU), leucovorin, irinotecan, liposomal irinotecan, oxaliplatin, gemcitabine, abraxane, erlotinib, capecitabine, and combinations thereof. In some embodiments, the patient has been administered a prior treatment for pancreatic cancer that is the standard of care using one or more agents selected from the group consisting of FOLFIRINOX (i.e. 5-FU+leucovorin+irinotecan+oxaliplatin), gemcitabine+abraxane, gemcitabine+erlotinib, gemcitabine, 5-FU+liposomal irinotecan, FOLFIRI (i.e. 5-FU+leucovorin+irinotecan), FOLFOX (i.e. 5-FU, oxaliplatin, leucovorin), and capecitabine+/−oxaliplatin.
- In some embodiments, the patient has been administered a prior treatment for uterine cancer (a.k.a. endometrial cancer), such as carboplatin, cisplatin, paclitaxel, docetaxel, doxorubicin, liposomal doxorubicin, trastuzumab, topotecan, bevacizumab, temsirolimus tamoxifen, fulvestrant, an aromatase inhibitor, and combinations thereof. In some embodiments, the patient has been administered a prior treatment for pancreatic cancer that is the standard of care using one or more agents selected from the group consisting of carboplatin+paclitaxel+/−trastuzumab, carboplatin or cisplatin+docetaxel, doxorubicin, or paclitaxel, liposomal doxorubicin, topotecan, bevacizumab, temsirolimus tamoxifen, fulvestrant, and an aromatase inhibitor.
- It will be appreciated that the agent that inhibits KRAS G12C for use in connection with the combination therapy described herein can be any agent that inhibits KRAS G12C as defined herein. Suitable examples of agent that inhibits KRAS G12C include antibodies of KRAS G12C, siRNAs, ribonucleic acids, peptides, oligonucleotides, small molecule inhibitors of KRAS G12C (as described herein), and the like. In some embodiments, the agent that inhibits KRAS G12C can be AMG-510, MRTX849, JNJ-74699157 (a.k.a. ARS-3248), ARS-1620, MRTX1257, RM-007 or ADT-007.
- For treatment purposes, pharmaceutical compositions comprising the compounds described herein may further comprise one or more pharmaceutically-acceptable excipients. A pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compounds described herein and are compatible with the active ingredient. Examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, anti-oxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents. In preferred embodiments, pharmaceutical compositions according to the invention are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art.
- Sterile compositions are also contemplated by the invention, including compositions that are in accord with national and local regulations governing such compositions.
- The pharmaceutical compositions and compounds described herein may be formulated as solutions, emulsions, suspensions, or dispersions in suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms. Pharmaceutical compositions of the invention may be administered by a suitable route of delivery, such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation. Preferably, the compositions are formulated for intravenous or oral administration.
- For oral administration, the compounds the invention may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension. To prepare the oral compositions, the compounds of the invention may be formulated to yield a dosage of, e.g., from about 0.1 mg to 2 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily. An alternative exemplary dose is in the range of about from about 0.1 mg/kg to 1 g/kg, or about 0.1 mg/kg to 5 mg/kg, or about 0.1 mg/kg to 1 mg/kg, or about 0.1 mg/kg to 0.6 mg/kg. Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like. Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
- Capsules for oral administration include hard and soft gelatin capsules. To prepare hard gelatin capsules, active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil, such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids,
polyethylene glycol 400, or propylene glycol. - Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
- For parenteral use, including intravenous, intramuscular, intraperitoneal, intranasal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 ug/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
- For nasal, inhaled, or oral administration, the inventive pharmaceutical compositions may be administered using, for example, a spray formulation also containing a suitable carrier. The inventive compositions may be formulated for rectal administration as a suppository.
- For topical applications, the compounds of the present invention are preferably formulated as creams or ointments or a similar vehicle suitable for topical administration. For topical administration, the inventive compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle. Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.
- Dosing and Administration
- In some embodiments of the methods and compositions described herein, a therapeutically effective amount of one or more compounds that inhibits FAK, SRC, and/or JAK2 in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C is administered to a host animal, such as a human patient, in need of treatment for cancer. In some embodiments of the methods and compositions described herein, a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C is administered to a host animal, such as a human patient, in need of treatment for cancer. - As used herein, the term “in combination with” refers to the administration of one or more compounds that inhibits FAK, SRC, and/or JAK2, in
particular Compound 1, with at least one agent that inhibits KRAS G12C. It will be appreciated that the administration of one or more compounds that inhibits FAK, SRC, and/or JAK2, inparticular Compound 1, “in combination with” administration of at least one agent that inhibits KRAS G12C at the same time as on another, where one or more compounds that inhibits FAK, SRC, and/or JAK2, inparticular Compound 1 is administered before at least one agent that inhibits KRAS G12C, or where one or more compounds that inhibits FAK, SRC, and/or JAK2, inparticular Compound 1 is administered after at least one agent that inhibits KRAS G12C. Furthermore, where the administration of one or more compounds that inhibits FAK, SRC, and/or JAK2, inparticular Compound 1, occurs at the same time as administration of at least one agent that inhibits KRAS G12C, the administered compounds can be co-formulated in a composition or medicament, or can be administered at the same time as separate compositions or medicaments. - As used herein, the term “therapeutically effective amount” refers to that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a patient, which includes alleviation of the symptoms of the disease or disorder being treated. In one aspect, the therapeutically effective amount is that which may treat or alleviate the disease or symptoms. The specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient: the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentally with the specific compound employed; and like factors.
- In some embodiments, a therapeutically effective amount of the combination can be a synergistic combination that provides an enhanced response to treatment with the combination when compared to when the one or more compounds that inhibits FAK, SRC, and/or JAK2 and the at least one agent that inhibits KRAS G12C are administered individually. In some embodiments, the synergistic effect provided by the administration of a therapeutically effective amount of the combination of the one or more compounds that inhibits FAK, SRC, and/or JAK2 and the at least one agent that inhibits KRAS G12C is a dose response that is more than additive compared to the response of the each of the components of the combination administered individually.
- In some embodiments, a therapeutically effective amount of the combination can be a synergistic combination that provides an enhanced response to treatment with the combination when compared to when the compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, and the at least one agent that inhibits KRAS G12C are administered individually. In some embodiments, the synergistic effect provided by the administration of a therapeutically effective amount of the combination of the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and the at least one agent that inhibits KRAS G12C is a dose response that is more than additive compared to the response of the each of the components of the combination administered individually. - In some embodiments, an exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g. It will be appreciated that all possible subranges within the dose ranges described above are contemplated and described herein. For example, a dose range of about 150 to about 500 mg for a compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, provided in the methods and compositions described herein includes doses of about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, including all possible doses and ranges as may be required based on such factors for determining a therapeutically effective amount as described herein. In some embodiments, the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, provided in the methods and compositions described herein can be dosed at about 40 mg, about 80 mg, about '120 mg, or about 160 mg. - In some embodiments, an exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg to about 3 g daily, or about 1 mg to about 50 mg daily, or about 50 to about 250 mg daily, or about 150 to about 500 mg daily, or about 150 to about 250 mg daily, or about 250 mg to about 1 g daily, or about 100 mg to about 2 g daily, or about 500 mg to about 2 g daily, or about 500 mg to about 1 g daily. It will be appreciated that all possible subranges within the daily dose ranges described above are contemplated and described herein. For example, a dose range of about 150 to about 500 mg daily for a compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, provided in the methods and compositions described herein includes doses of about 150 mg daily, about 160 mg daily, about 170 mg daily, about 180 mg daily, about 190 mg daily, about 200 mg daily, about 210 mg daily, about 220 mg daily, about 230 mg daily, about 240 mg daily, and about 250 mg daily, about 260 mg daily, about 270 mg daily, about 280 mg daily, about 290 mg daily, about 300 mg daily, about 310 mg daily, about 320 mg daily, about 330 mg daily, about 340 mg daily, about 350 mg daily, about 360 mg daily, about 370 mg daily, about 380 mg daily, about 390 mg daily, about 400 mg daily, about 410 mg daily, about 420 mg daily, about 430 mg daily, about 440 mg daily, about 450 mg daily, about 460 mg daily, about 470 mg daily, about 480 mg daily, about 490 mg daily, about 500 mg daily, including all possible doses and ranges as may be required based on such factors for determining a therapeutically effective amount as described herein. In some embodiments, the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, provided in the methods and compositions described herein can be dosed at about 40 mg daily, about 80 mg daily, about '120 mg daily, or about 160 mg daily. - In some embodiments, an alternative exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg. It will be appreciated that all possible subranges within the dose ranges described above are contemplated and described herein. For example, a dose range of about 1.0 mg/kg to about 10 mg/kg for a compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, provided in the methods and compositions described herein includes doses of about 1.0 mg/kg, about 2.0 mg/kg, about 3.0 mg/kg, about 4.0 mg/kg, about 5.0 mg/kg, about 6.0 mg/kg, about 7.0 mg/kg, about 8.0 mg/kg, about 9.0 mg/kg, and about 10.0 mg/kg, including all possible doses and ranges as may be required based on such factors for determining a therapeutically effective amount as described herein. - In some embodiments, an alternative exemplary dose for each compound or agent individually in the various methods and compositions described herein is in the range of about from about 0.1 mg/kg to about 1 g/kg daily, or about 0.5 mg/kg to about 50 mg/kg daily, or about mg/kg to about 25 mg/kg daily, or about 1.0 mg/kg to about 10 mg/kg daily, or about 1.0 mg/kg to about 5 mg/kg daily, or about 0.1 mg/kg to about 5 mg/kg daily, or about 0.1 mg/kg to about 1 mg/kg daily, or about 0.1 mg/kg to about 0.6 mg/kg daily. It will be appreciated that all possible subranges within the dose ranges described above are contemplated and described herein. For example, a dose range of about 1.0 mg/kg to about 10 mg/kg daily for a compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, provided in the methods and compositions described herein includes doses of about 1.0 mg/kg daily, about 2.0 mg/kg daily, about 3.0 mg/kg daily, about 4.0 mg/kg daily, about 5.0 mg/kg daily, about 6.0 mg/kg daily, about 7.0 mg/kg daily, about 8.0 mg/kg daily, about 9.0 mg/kg daily, and about 10.0 mg/kg daily, including all possible doses and ranges as may be required based on such factors for determining a therapeutically effective amount as described herein. - It will be appreciated that various dosing schedules for administration of each compound or agent administered individually (or together) can be applied to the methods and compositions described herein. It will be further appreciated that a dosing schedule for each compound or agent administered individually (or together) in the various methods and compositions described herein can be defined by cycles of the dosing schedule, where such cycles are defined by the number of days of treatment, number of doses of each compound or agent individually (or together), the total dose of each compound or agent individually (or together), and the like. In some embodiments, a host animal, such as a human patient in need of treatment, can be administered each compound or agent administered individually (or together) for at least one cycle, for at least two cycles, for at least three cycles, for at least four cycles, and the like. Alternatively, in some embodiments, a host animal, such as a human patient in need of treatment, can be administered each compound or agent administered individually (or together) for from 1 to about 50 cycles, from 1 to about 25 cycles, from 1 to about 20 cycles, from 1 to about 10 cycles, and the like. It will be appreciate that, in some embodiments, a dosing schedule for each compound or agent administered individually (or together) in the various methods and compositions described herein can include a holiday period during which no compound or agent is administered, and such holiday period can be measured in days. In some embodiments, a dosing schedule for each compound or agent administered individually (or together) in the various methods and compositions described herein can be defined by a number of cycles as described herein, followed by a holiday period, followed by another number of cycles as described herein.
- In some embodiments, an exemplary dosing schedule for each compound or agent individually in the various methods and compositions described herein can include administration of a single daily dose (QD) or divided dosage units (e.g., BID (twice daily), TID (three times daily), QID (four times daily)). In some embodiments, a dosing schedule for each compound or agent in the various methods and compositions described herein can be the same, such as all compounds or agents in the various methods and compositions described herein are administered QD, BID, or the like. In some embodiments, a dosing schedule for each compound or agent in the various methods and compositions described herein can be different from each other, such as one compound or agent in the various methods and compositions described herein is administered QD, and another compound or agent in the various methods and compositions described herein is administered BID. In some embodiments, a dosing schedule for each compound or agent in the various methods and compositions described herein can vary within a cycle, such as one compound or agent in the various methods and compositions described herein administered QD for a set number of days (e.g. QD for 1 day, 2 days, 3 days, 4 days, etc) followed by BID for a set number of days (e.g. BID for 1 day, 2 days, 3 days, 4 days, etc). In some embodiments, a dosing schedule for each compound or agent in the various methods and compositions described herein can be the same or different within a cycle, such as one compound or agent in the various methods and compositions described herein administered QD for a set number of days (e.g. QD for 1 day, 2 days, 3 days, 4 days, etc) followed by BID for a set number of days (e.g. BID for 1 day, 2 days, 3 days, 4 days, etc) to match the length of the cycle, and another compound or agent administered BID for a set number of days to match the length of the cycle.
- In some embodiments, the compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, and the agent that inhibits KRAS G12C are administered at the same time. In some embodiments, the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and the agent that inhibits KRAS G12C are individually formulated, and administered at the same time. In some embodiments, the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and the agent that inhibits KRAS G12C are individually formulated, and administered in sequence. In some embodiments, the sequential administration of the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and the agent that inhibits KRAS G12C can be accomplished with the compound that inhibits FAK, SRC and JAK2, inparticular Compound 1, administered first (e.g. in the morning), and the agent that inhibits KRAS G12C administered second (e.g. in the afternoon or evening). In some embodiments, the sequential administration of the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and the agent that inhibits KRAS G12C can be accomplished with agent that inhibits KRAS G12C administered first (e.g. in the morning), and the compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, administered second (e.g. in the afternoon or evening). - In some embodiments, an exemplary dosing schedule for each compound or agent individually in the various methods and compositions described herein can include administration of a compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, at a dose level of from about 100 mg to about 300 mg QD for at least one day followed by a dose level of from about 100 mg to about 300 mg BID and an agent that inhibits KRAS G12C, in particular AMG510, at a dose level of from about 800 mg to about 1.5 g QD. In some embodiments, the administration of a compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and an agent that inhibits KRAS G12C, in particular AMG510, on the dose schedule described above can be given for from 1 to about 20 cycles, where each cycle is from about 5 to about 20 days. In some embodiments, the administration of a compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and an agent that inhibits KRAS G12C, in particular AMG510, on the dose schedule described above can be given for a set number of days, such as from about 20 to about 200 days, perpetually, or until treatment is stopped by a treating physician. - In some embodiments, an exemplary dosing schedule for each compound or agent individually in the various methods and compositions described herein can include administration of a compound that inhibits FAK, SRC, and JAK2, in
particular Compound 1, at a dose level of from about 100 mg to about 300 mg QD for at least one day followed by a dose level of from about 100 mg to about 300 mg BID and an agent that inhibits KRAS G12C, in particular MRTX849, at a dose level of from about 500 mg to about 1 g BID. In some embodiments, the administration of a compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and an agent that inhibits KRAS G12C, in particular MRTX849, on the dose schedule described above can be given for from 1 to about 20 cycles, where each cycle is from about 5 to about 20 days. In some embodiments, the administration of a compound that inhibits FAK, SRC, and JAK2, inparticular Compound 1, and an agent that inhibits KRAS G12C, in particular MRTX849, on the dose schedule described above can be given for a set number of days, such as from about 20 to about 200 days, perpetually, or until treatment is stopped by a treating physician. - Chemicals and Reagents
-
Compound 1 was prepared according to the methods described in WO2015/112806, see specifically Example 90 as described therein. WO2015/112806 is incorporated herein by reference for the preparation ofCompound 1. - AMG510 was purchased from Active Biochem (catalog number A-9132). Drugs were prepared in dimethyl sulfoxide (DMSO) at a concentration of 10-100 mmol/L stock solutions and stored at −20° C. Further dilutions were made in culture medium to final concentration before use. Phospho—STAT3 (Tyr705), phospho-AKT (Ser473), phospho-ERK1/2 (Thr202/Tyr204), phospho-FAK (Tyr576/577), STAT3, FAK, SRC, AKT, ERK, PARP, cleaved caspase-3, tubulin, and actin were purchased from Cell Signaling Technology (Beverly, MA).
- Cell Lines
- Human NSCLC cell lines H358, H23, H2122, H1373 and H1792, harboring KRAS G12C mutation, were purchased from the American Type Culture Collection (ATCC). All cell lines were maintained in RPMI (Roswell Park Memorial Institute medium) 1640 supplemented with 1% penicillin/ streptomycin/ glutamine (Gibco) and 10% fetal bovine serum (FBS) (Gibco) in 5% CO2, 37° C. cell culture incubator and were routinely evaluated for mycoplasma contamination. In-Vitro Assays
- Two thousand cells per well were seeded in 96 or 384 well white plate, and then treated with indicated compounds for 72 hours (37° C., 5% CO2). Cell proliferation was measured using CellTiter-Glo luciferase-based ATP detection assay (Promega) following the manufactures's protocol. IC50 determinations were performed using GraphPad Prism software (GraphPad, Inc., San Diego, CA).
- Results showing cell viability % of the KRAS G12C inhibitor (AMG510),
Compound 1, and the combination of the KRAS inhibitor AMG510 with Compound 1 (1 μM) in KRAS G12C mutated H358, H23, H2122, H1373 and H1792 cells are summarized in Table 1. Although H358, H23, H2122, H1373 and H1792 NSCLC cell line endogenously expresses KRAS G12C mutation, the KRAS G12C inhibitor AMG510 demonstrated moderate to weak inhibition of the cell proliferation. We investigated the synergistic effect of Compound 1 (11.04) in combination with AMG510 on cell proliferation in H358, H23, H2122, H1373 and H1792 NSCLC cell lines with KRAS G12C mutation.Compound 1 alone had only weak inhibition activity to H358, H23, H2122, H1373 and H1792 NSCLC cell line with IC50 ranges from 1.9 to 5 μM. A strong synergy was observed with the combination of AMG510 andCompound 1.Compound 1 at 11.04 concentration shifted AMG510′s IC50 from 213nM to 3 nM against H358 cell proliferation. The combination caused much more complete cell proliferation suppression compared to AMG510 treatment alone in H23, H2122, H1372, and H1792 NSCLC cell lines harboring the KRAS G12C mutation. -
TABLE 1 IC50s (nM) Cell lines AMG-510 + (KRAS mutation) Compound 1AMG-510 Compound 1 (1 μM) H358 (G12C) 2500 213 3 H23 (G12C) 4059 >10000 ~1500 H2122 (G12C) 1936 530.3 90.5 H1373 (G12C) ~5000 >10000 355.7 H1792 (G12C) 1901 >10000 ~3000 - Results showing cell viability % of the KRAS G12C inhibitor MRTX849,
Compound 1, and the combination of the KRAS inhibitor MRTX849 with Compound 1 (1 μM) in KRAS G12C mutated H358, and H2122 cells were also determined. We investigated the effect of Compound 1 (1 μM) in combination with MRTX849 on cell proliferation in H358 and H2122 NSCLC cell lines with KRAS G12C mutation.Compound 1 at 1 μM concentration shifted MRTX849's IC50 from 75nM to 11 nM against H358 cell proliferation and from 182 nM to 42 nM against H2122 cell proliferation. - Results showing cell viability % of the KRAS G12C inhibitor ARS-1620,
Compound 1, and the combination of the KRAS inhibitor ARS-1620 with Compound 1 (1 μM) in KRAS G12C mutated H358, and H2122 cells were determined. We investigated the effect of Compound 1 (1 μM) in combination with ARS-1620 on cell proliferation in H358 and H2122 NSCLC cell lines with KRAS G12C mutation.Compound 1 at 1 μM concentration shifted ARS-1620's IC50 from 488 nM to 88 nM against H358 cell proliferation and from 1287 nM to 52 nM against H2122 cell proliferation. - Two thousand cells per well were seeded in 384 well white plate, and then treated with compounds for 24 or 48 hours (37° C., 5% CO2). Cell caspase-3/7 activity, a major hallmark of apoptosis, was measured using Caspase-
Glo® 3/7 detection assay (Promega) following the manufactures's protocol. Results showing the increase of caspase-3/7 activity with 24 and 48 hour treatments of AMG510 (50 nM), Compound 1 (111.M), and the combination of AMG510 (50 nM) with Compound 1 (1 μM) in NSCLC cell lines harboring a KRAS G12C mutation (H358, H2122, H1373) are shown inFIG. 1 a-1 f .Compound 1 alone increased caspase-3/7 activity in H358 and H2122 NSCLC cell lines (FIGS. 1 a-1 d ). AMG510 alone increased caspase-3/7 activity with H358, H2122, and H1373 NSCLC cell lines (FIGS. 1 a-1 f ). The combination ofCompound 1 with AMG510 caused more caspase-3/7 activation compared to AMG510 treatment alone for NSCLC cells with a G12C mutation (FIGS. 1 a-1 f ) at both 24 and 48 hour timepoints. - Cleaved PARP and cleaved caspase-3 were evaluated as biomarkers of apoptosis. Half a million cells per well were seeded in 24 well plate for 24 hrs, and then treated with compounds for 4, 24 or 48 hours. Cells were collected after treatment and lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS) supplemented with 10 mM EDTA, 1× Halt protease and phosphatase inhibitors (Thermo Scientific). Protein lysates (approximately 20 pg) was resolved on 4-12% Bolt Bis-Tris precasted gels with MES running buffer (Life Technologies), transferred to nitrocellulose membranes using Trans-Blot Turbo Transfer System (Bio-Rad) and detected with antibodies targeting PARP, Cleaved caspase-3, tubulin and actin (Cell Signaling Technology). Antibodies were typically incubated overnight at 4° C. with gentle shake, followed by washes and incubation with the appropriate HRP-conjugated secondary antibodies. Membranes were incubated with chemiluminescent substrate for 5 min at room temperature (SuperSignal West Femto, Thermo Scientific). The chemiluminescent images were acquired with a C-DiGit Imaging System (LI-COR Biosciences). Results in the H358 KRAS G12C NSCLC cell line demonstrated large increases in cleaved PARP and cleaved caspase-3 after both 24 and 48 hour treatments with the combination of AMG510 (100 nM) and Compound 1 (1 Treatment with AMG510 alone (100 nM) or
Compound 1 alone (1 μM) resulted in small increases in cleaved PARP and cleaved caspase-3 protein. Activation of apoptosis was demonstrated by cleaved PARP and cleaved caspase-3 in H358 mutant KRAS G12C NSCLC cells after 24 hr or 48 hr with AMG510 (100 nM), Compound 1 (1 μM), and the combination of AMG510 (100 nM) and Compound 1 (1 μM) after 48 hrs. Results in H2122 KRAS G12C NSCLC demonstrated large increases in cleaved PARP and cleaved caspase-3 after 48 hour treatment with the combination of AMG510 (100 nM) and Compound 1 (1 Treatment with AMG510 (100 nM) alone or Compound 1 (1 μM) alone had minimal-to-no increases in increased cleaved PARP and cleaved caspase-3 which was strikingly less than the combination ofCompound 1 and AMG510. The activation of apoptosis was also demonstrated by cleaved PARP and cleaved caspase-3 in H2122 mutant KRAS G12C NSCLC cells after 48 hour treatment with AMG510 (100 nM), Compound 1 (1 and the combination of AMG510 (100 nM) and Compound 1 (1 - Half a million cells per well were seeded in 6 well or 24 well plate for 24 hrs, and then treated with compounds for 4, 24 or 48 hours. Cells were collected after treatment and lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Deoxycholate, 0.1% SDS) supplemented with 10 mM EDTA, 1× Halt protease and phosphatase inhibitors (Thermo Scientific). Protein lysates (approximately 20 pg) was resolved on 4-12% Bolt Bis-Tris precasted gels with IVIES running buffer (Life Technologies), transferred to nitrocellulose membranes using Trans-Blot Turbo Transfer System (Bio-Rad) and detected with antibodies targeting phosphorylated STAT3, FAK, SRC, HER2, AKT, ERK, S6 (Cell Signaling Technology), total STAT3, FAK, SRC, HER2, AKT, S6 ERK and cleaved caspase 3 (Cell Signaling Technology). Antibodies were typically incubated overnight at 4° C. with gentle shake, followed by washes and incubation with the appropriate HRP-conjugated secondary antibodies. Membranes were incubated with chemiluminescent substrate for 5 min at room temperature (SuperSignal West Femto, Thermo Scientific). The chemiluminescent images were acquired with a C-DiGit Imaging System (LI-COR Biosciences). The inhibition of phosphorylation of STAT3, ERK, AKT, and FAK by Compound 1 (1 μM), AMG510 (100 nM), and Compound 1 (1 μM)+AMG510 (100 nM) was measured after 4, 24, and 48 hrs.
- Results in H358 KRAS G12C NSCLC showed that
Compound 1 alone suppressed protein levels of phospho—STAT3 (pSTAT3), phospho-FAK (pFAK) at 4, 24 and 48 h time points. AMG510 did not suppress pSTAT3 or pFAK protein levels at any time point. The combination ofCompound 1 and AMG510 suppressed pFAK and pSTAT3 protein levels at all time points.Compound 1 alone did not suppress phospho-ERK (PERK) at any time point. AMG510 did not suppress pERK at 4 hours of treatment but does after 24 and 48 hours of treatment. The combination ofCompound 1 with AMG510 suppressed pERK at all timepoints. Treatment withCompound 1 alone or AMG510 alone had minimal-to-no suppression of phospho-AKT (pAKT) with treatments up to 24 hours. Treatment of 48 hours with AMG510 alone increased pAKT while 48 treatment withCompound 1 alone decrease pAKT relative to control. The combination ofCompound 1 with AMG510 had significant suppression of pAKT after 24 and 48 hours of treatment, which support the significantly increased activation of apoptosis in the combination treatment. - The inhibition of phosphorylation of FAK, STAT3, SRC, HER2, ERK, AKT, and S6 and the activation of apoptosis by cleaved caspase-3 by Compound 1 (1 μM), MRTX849 (100 nM), and Compound 1 (1 μM)+MRTX849 (100 nM) was evaluated in H2122 mutant KRAS G12C NSCLC cells after 4 hrs, 24 hrs and 48 hrs. Results in H2122 KRAS G12C NSCLC show that
Compound 1 alone suppressed protein levels of phospho—STAT3 (pSTAT3), phospho-FAK (pFAK) and phospho—SRC at 4, 24 and 48 h time points. MRTX849 did not suppress pSTAT3, pFAK or pSRC protein levels at any time point. The combination ofCompound 1 and MRTX849 suppressed pFAK, pSTAT3 and pSRC protein levels at all time points.Compound 1 alone did not suppress phospho-ERK (pERK) at any time point while MRTX849 suppresses pERK at all time points. The combination ofCompound 1 with MRTX849 suppressed pERK at all timepoints. Treatment withCompound 1 alone or MRTX849 alone suppressed phospho-AKT (pAKT) at all time points. Treatment of 48 hours with MRTX849 alone increased pHER2. The combination ofCompound 1 with MRTX849 had enhanced suppression of pAKT and p-S6 after 4, 24 and 48 hours of treatment than either agent alone and suppressed pHER2 at 48 hours which support the significantly increased activation of apoptosis as demonstrated by cleaved caspase-3 in the combination treatment. - The inhibition of phosphorylation of FAK, STAT3, SRC, ERK, AKT, and S6 by Compound 1 (1 μM), ARS1620 (1 μM), and Compound 1 (1 μM)+ARS1620 (1 μM) was evaluated in H358 mutant KRAS G12C NSCLC cells after 4 hrs, 24 hrs and 48 hrs. Results in H358 KRAS G12C NSCLC show that
Compound 1 alone suppressed protein levels of phospho-STAT3 (pSTAT3), phospho-FAK (pFAK) and phospho—SRC at 4, 24 and 48 h time points. ARS1620 did not suppress pSTAT3, pFAK or pSRC protein levels at any time point. The combination ofCompound 1 and ARS1620 suppressed pFAK, pSTAT3 and pSRC protein levels at all time points. The combination ofCompound 1 with ARS1620 suppressed pERK at all timepoints. Treatment withCompound 1 alone or ARS1620 alone suppressed phospho-AKT (pAKT) with treatments up to 24 hours. Treatment of 48 hours with ARS1620 alone increased pAKT while 48 treatment withCompound 1 alone decrease pAKT relative to control. The combination ofCompound 1 with ARS1620 had significant suppression of pAKT and p-S6. - Results in H2122 KRAS G12C NSCLC show that
Compound 1 alone suppressed protein levels of phospho-STAT3 (pSTAT3), phospho-FAK (pFAK) and phospho—SRC at 4, 24 and 48 h time points. ARS1620 did not suppress pSTAT3, pFAK or pSRC protein levels at any time point. The combination ofCompound 1 and ARS1620 suppressed pFAK, pSTAT3 and pSRC protein levels at all time points.Compound 1 alone did not suppress phospho-ERK (pERK) at any time point while ARS1620 suppressed pERK at 4 and 24 hours. The combination ofCompound 1 with ARS1620 suppressed pERK at at 4 and 24 hours. Treatment withCompound 1 alone or ARS1620 alone suppressed phospho-AKT (pAKT) at all time points. The combination ofCompound 1 with ARS1620 showed significant enhanced suppression of pAKT and p-S6 than ARS1620 treatment alone. - H2122 NSCLC cells were used to identify synergistic combinations between AMG-510 or MRTX-849 and
Compound 1. One 96-well plate was seeded with 2000 cells/well in a total volume of 80μ1 of RPMI supplemented with 10% fetal bovine serum (FBS). The following day, a combination matrix was generated comprising a horizontally diluted drug titration of AMG-510 or MRTX-849 (final concentration of 10 μM diluted 3-fold down to 1.5 nM) with a vertically titrated Compound 1 (final concentration of 3μM to 37 nM diluted 3 fold). The cells were incubated for 96 hours at 37C in 5% CO2. Subsequently, 36 μl of Cell-Titer Glo reagent (Promega) was added to each well and the plates were incubated for 10 min at 37C. Luminescence was quantitated using a Synergy H1 microplate plate reader (Biotek) according to the manufacturer's instructions. Synergy was assessed by BLISS independence analysis on the Synergyfinder website (Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017 Aug. 1; 33(15):2413-2415). - In the in vitro combination screen, KRAS inhibitors (AMG-510 and MRTX-849) and
Compound 1 demonstrated synergy in H2122 cells. A visualization of the dose response matrix are shown inFIGS. 2 a-2 b . Table 2 shows the Bliss synergy scores for relevant drug doses. -
TABLE 2 Compound 1BLISS Synergy Score AMG-510 41 nM 1000 nM 21 123 nM 1000 nM 16 MRTX-849 41 nM 1000 nM 7 123 nM 1000 nM 12 - Cytokines and Growth Factors Evaluated
- ENA-78 (CXCL5), GCSF, GM-CSF, GRO alpha/beta/gamma, GRO alpha (CXCL1), I-309 (TCA-3/CCL1), IL-1 alpha (IL-1 F1), IL-1 beta (IL-1 F2), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12 p40/p70, IL-13, IL-15, IFN-gamma, MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (MARC/CCL7), M-CSF, MDC (CCL22), MIG (CXCL9), MIP-1 beta (CCL4), MIP-1 delta (CCL15), RANTES (CCL5), SCF, SDF-1 alpha (CXCL12 alpha), TARC (CCL17), TGF beta 1, TNF alpha, TNF beta (TNFSF1B), EGF, IGF1, Angiogenin, Oncostatin M, Thrombopoietin (TPO), VEGF-A, PDGF-BB, Leptin, BDNF, BLC (CXCL13), Ck beta 8-1 (CCL23), Eotaxin-1 (CCL11), Eotaxin-2 (MPIF-2/CCL24), Eotaxin-3 (CCL26), FGF-4, FGF-6, FGF-7 (KGF), FGF-9, Flt-3 Ligand, Fractalkine (CX3CL1), GCP-2 (CXCL6), GDNF, HGF, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IL-16, IP-10 (CXCL10), LIF, Light (TNFSF14), MCP-4 (CCL13), MIF, MIP-3 alpha (CCL20), NAP-2 (PPBP/CXCL7), NT-3, NT-4, Osteopontin (SPP1), Osteoprotegerin (TNFRSF11B), PARC (CCL18), PLGF, TGF beta 2, TGF beta 3, TIMP-1, TIMP-2.
- Experimental Method
- Cytokine Array
- Cytokines present in NCI-H358 and NCI-H2122 conditioned media were identified and quantitatively compared using Human Cytokine Antibody Array C5 (AAH-CYT-5-8, RayBiotech). One million cells per well were seeded in 6 well plates and allowed to attach for 24 h, and then treated with AMG-510 (100 nM)/MRTX849 (100 nM), Compound 1 (1 μM) or the combination of AMG-510 (100 nM)/MRTX849 (100 nM) and Compound 1 (1 μM) for 24 or 48 hours. Antibody arrays were blocked for 30 minutes at room temperature, following incubation with conditioned media from H358 and H2122 cells overnight at 4° C. Antibody arrays were then washed and re-incubated with the biotinylated antibody cocktail overnight at 4° C., followed with HRP-conjugated streptavidin for 2 h at room temperature. Following a final wash step, chemiluminescence detection buffers were added to arrays and chemiluminescence signals were captured using a iBright 1500 imaging system (Invitrogen). The spot density was quantified by using the iBright Analysis Software and compared using the RayBiotech Analysis tool for AAH-CYT-5.
- ELISA
- Half a million cells per well were seeded in 6 well plates and allowed to attach for 24 hrs, and then treated with AMG-510 (100 nM)/MRTX849 (100 nM), Compound 1 (1 μM) or the combination of AMG-510 (100 nM)/MRTX849 (100 nM) and Compound 1 (1 μM) for 48 hours. To assess IL-6 secretion by tumor cells, supernatants were harvested and human IL-6 ELISA assays were performed per manufacturer's instructions (R&D Biosystems). Briefly, microplate wells were incubated with either the standard, control and sample supernatants from H358 and H2122 cells for 2 hours at room temperature. Microplates were then washed and incubated with human IL-6 conjugate for 2 hours at room temperature, followed by washing and addition of substrate solution for 20 minutes. Finally stop solution is added and optical density evaluated using a microplate reader set to 450 nm. Readings at 540 nm were substracted to correct for optical imperfections in the plate.
- qPCR
- Half a million cells per well were seeded in 6 well plates and allowed to attach for 24 hrs, and then treated with AMG-510 (100 nM)/ MRTX849 (100 nM), Compound 1 (1 μM) or the combination of AMG-510 (100 nM)/MRTX849 (100 nM) and Compound 1 (1 μM) for 24 and 48 hours. mRNA was prepared using the Rneasy Mini Kit (Qiagen) and cDNA synthesized using SuperScript IV VILO (Invitrogen). qPCR was carried out with diluted cDNA, appropriate Taqman probes and Taqman Fast Advanced Master mix (Applied Biosystems) using a
QuantStudio 5 Thermal Cycler (Applied Biosystems). Relative mRNA levels were calculated using the 2-Ct method, using RPL32 as an internal control. - KRAS cell lines H358 and H2122 shown to secrete IL-6, and IL-6 is shown to be inhibited by
Compound 1 alone and in the presence of AMG510, where the inhibition of IL-6 secretion is greater in the combination ofCompound 1 and AMG-510, than with either compound individually. Results are shown inFIGS. 3 a -3 d. - Cytokine data was also generated in H2122 NSCLC cell lines treated for 48 h with a combination of
Compound 1 with MRTX849. (a) Control; (b) MRTX849; (c)Compound 1; (d)Compound 1+MRTX849 (FIG. 3 e ). - KRAS cell line H2122 shown to secrete IL-6, and IL-6 is shown to be inhibited by
Compound 1 alone and in the presence of MRTX849, where the inhibition of IL-6 secretion is greater in the combination ofCompound 1 and MRTX849, than with either compound individually (FIGS. 3 f-3 g ). - Method 1: Subcutaneous Xenograft Models in Immune Compromised Mice
- Female athymic nude, SCID, NOD/SCID or SCID/Beige mice (5-8 weeks of age) were used as host mice. For subcutaneous cell-derived xenograft models, about five million cells in 100 μL serum-free medium supplemented with 50% matrigel (Corning, Inc) were implanted subcutaneously in the right flank region of each host mouse. For subcutaneous patient-derived xenograft models, a tumor fragment from host mice was implanted subcutaneously in the flank region of each host mouse. Tumor size and body weight were measured on designated days. Tumor size was measured with an electronic caliper and tumor volume was calculated as the product of length*
width 2*0.5 or similar formula. Mice were randomized by tumor size into treatment groups when mean tumor volume reached a certain size.Compound 1 was administered orally twice a day at determined doses and AMG-510 was administered orally once a day at determined doses. For brain orthotopic models, about 80000 cells were implanted into brain and treatment of mice with control or test articles started 7 days post the implantation. - Method 2: Tumor Processing and Immunoblotting for in vivo Pharmacodynamic Studies
- Mice bearing xenograft tumors were humanely euthanized and tumors were resected and snap frozen in liquid nitrogen and stored at −80° C. Frozen tumor samples were processed at 4° C. in RIPA buffer to extract proteins. Protein concentration of the lysate was determined by Rapid Gold BCA Protein Assay (Life Technologies, Inc.) and lysate were diluted to ensure the same protein concentration across samples. SDS loading samples were prepared by adding one volume of 4× LDS Sample Buffer (Life Technologies, Inc.) to three volumes of diluted protein lysate. Tumor SDS protein samples were processed by SDS-PAGE and immunoblotted appropriate primary antibodies, followed by detection using HRP conjugated secondary antibodies. The signals from immunoblot were detected by C-DiGit Blot Scanner from LI-COR using the Image Studio Digit software (LI-COR).
- H358 cells harbor a KRAS G12C mutation. SCID/Beige mice bearing H358 cell-derived tumors were treated with vehicle BID,
Compound 1 BID at 15 mg/kg, AMG-510 QD at 10 mg/kg, andCompound 1 BID at 15 mg/kg in combination with AMG-510 QD at 10 mg/kg, respectively. The tumor volume (TMV) vs time data are shown as mean±sem inFIG. 4 a . After 26 days of treatment,Compound 1 in combination with AMG-510 significantly reduced tumor volume compared to the treatment with vehicle,Compound 1 only or AMG-510 only (p<0.0001 for all three comparisons, post hoc Tukey's multiple comparison test following two-way repeated measures ANOVA analysis). Body weight of the mice were measured during treatment and are shown as mean±sem inFIG. 4 b . There is no statistical significance among treatment groups (p=0.4233, two-way repeated measures ANOVA), suggesting that the combination treatment ofCompound 1 and AMG-510 did not resulted in any body weight loss or overt abnormality under these experimental conditions. - To evaluate the pharmacodynamic effect of
Compound 1 in combination with AMG-510 in H358 cell-derived xenograft tumors, tumor lysate was prepared and analyzed by immunoblotting using antibodies against the candidate molecules selected from signaling pathways that can be potentially modified byCompound 1 and/or AMG-510. The inhibitory activities ofCompound 1 against SRC and JAK2 were demonstrated by the reduction of phosphorylated SRC (Y416) and STAT3 (Y705) signals in tumors treated byCompound 1 either as the single agent or in combination with AMG-510, compared to vehicle treatment. In addition, the activity ofCompound 1 against FAK was shown by the reduced the phosphorylated FAK signal inCompound 1 and AMG-510 combination treatment group. Moreover, the AMG-510 activity against KRAS was illustrated by the reduced level of phosphorylated ERK (T202/Y204) signal, a key downstream effector of KRAS signaling in mice treated by AMG-510 either as a single agent or in combination withCompound 1. Finally, combination ofCompound 1 with AMG-510 also reduced the phosphorylated AKT (S473) signal, a key factor involved in cell survival and proliferation. Therefore,Compound 1 and AMG-510 combinatory treatment not onlyCompound 1 and AMG-510 targets, including SRC, FAK, JAK2, and KRAS, but also suppress the activity of AKT, a key factor for the PI3K-AKT oncogenic pathway. - LU11693 PDX tumors harbor a KRAS G12C mutation. NOD/SCID mice bearing LU11693 PDX tumors were treated with vehicle BID,
Compound 1 BID at 15 mg/kg, AMG-510 QD at 100 mg/kg, andCompound 1 BID at 15 mg/kg in combination with AMG-510 QD at 100 mg/kg, respectively. The tumor volume vs time data are shown as mean ±sem inFIG. 5 a . Body weight of the mice were measured during treatment and are shown as mean ±sem inFIG. 5 b . Treatment with AMG-510 at 100 mg/kg QD either as a single agent or in combination withCompound 1 significantly reduced body weight of mice. Onday 13, two mice in the combination treatment groups were euthanized due to the loss of body weight and the dose of AMG-510 was reduced to 30 mg/kg QD starting onday 14 in both AMG-510 only treatment and theCompound 1 and AMG-510 combination treatments. After 21 days of treatment,Compound 1 in combination with AMG-510 significantly reduced tumor volume compared to the treatment compared to the treatment with vehicle,Compound 1 only or AMG-510 only (p=0.0002 vs vehicle, p=0.0181 vsCompound 1, p=0.0003 vs AMG-510, post hoc Dunnett's multiple comparison test following mixed-effect model). As stated above, body weight loss was observed in mice treated with AMG-510 at 100 mg/kg QD either as a single agent or in combination withCompound 1. After dose reduction, the body weight in theCompound 1 plus AMG-510 combination group start to recover and, onday 21, the body weight in the combination group is not significant different from the vehicle treated group (p=0.5487 vs vehicle, Dunnett's multiple comparisons test following one-way ANOVA). - The effect of
Compound 1 and AMG-510 combination treatment on survival of tumor bearing mice was evaluated using the H2122 cell-derived xenograft tumor model with the KRAS G12c mutation. Starting onday 5 post tumor cell implantation, SCID/Beige mice bearing H2122 cell-derived xenograft tumors were randomized in to groups (n=10 for each group) based on tumor size and treated with vehicle BID,Compound 1 BID at 15 mg/kg, AMG-510 QD at 10 mg/kg,Compound 1 BID at 15 mg/kg in combination with AMG-510 QD at 10 mg/kg, AMG-510 QD at 30 mg/kg, andCompound 1 BID at 15 mg/kg in combination with AMG-510 QD at mg/kg, respectively. To evaluate the survial effect, individual mouse was considered dead if it reached one of the humane end points: moribund status, tumor volume over 2000 mm3, more than 20% body weight loss compared to baseline, open tumor lesions, and inability to eat or drink. The study ended on day 101 post tumor cell implantation. The median survival were 34, 52, 77, and 76.5 days for the groups treated with vehicle BID,Compound 1 BID at 15 mg/kg, AMG-510 QD at 10 mg/kg,Compound 1 BID at 15 mg/kg in combination with AMG-510 QD at mg/kg, and AMG-510 QD at 30 mg/kg, respectively; and the median survival was not reached for the group treated withCompound 1 BID at 15 mg/kg in combination with AMG-510 QD at 30 mg/kg when the study was terminated on day 101 post the tumor cell implantation. At mg/kg dose level of AMG-510, treatment withCompound 1 in combination with AMG-510 statistically significantly increased the median survival compared to the treatment with AMG-510 only (p<0.0019, Log-rank test,Compound 1 and AMG-510 combination vs AMG-510,FIG. 6 a ). At 30 mg/kg dose level of AMG-510, treatment withCompound 1 in combination with AMG-510 statistically significantly increased the median survival compared to the treatment with AMG-510 only (p<0.0138, Log-rank test,Compound 1 and AMG-510 combination vs AMG-510,FIG. 6 b ). These findings suggest that combination treatment ofCompound 1 and AMG-510 prolonged the survival of the mice bearing H2122 cell-derived tumors compared to AMG-510 single agent treatment.
Claims (20)
1. A method for treating cancer in a host animal, the method comprising the step of administering to the host animal a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C, wherein the compound is
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the cancer is selected from the group consisting of ALCL, non-small cell lung cancer, neuroblastoma, inflammatory myofibroblastic tumor, adult renal cell carcinoma, pediatric renal cell carcinoma, breast cancer, triple negative breast, colonic adenocarcinoma, glioblastoma, glioblastoma multiforme, anaplastic thyroid cancer, cholangiocarcinoma, ovarian cancer, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, epithelioid hemangioendothelioma, intrahepatic cholangiocarcinoma, thyroid cancer, spitzoid neoplasms, sarcoma, astrocytoma, brain lower grade glioma, secretory breast carcinoma, mammary analogue carcinoma, acute myeloid leukemia, congenital mesoblastic nephroma, congenital fibrosarcomas, Ph-like acute lymphoblastic leukemia, thyroid carcinoma, head and neck squamous cell carcinoma, pediatric glioma CML, prostate cancer, lung squamous carcinoma, ovarian serous cystadenocarcinoma, skin cutaneous melanoma, castrate-resistant prostate cancer, Hodgkin lymphoma, serous and clear cell endometrial cancer, oral cancer, endometrial cancer, endocrine cancer, skin cancer, gastric cancer, esophageal cancer, laryngeal cancer, pancreatic cancer, colon cancer, bladder cancer, bone cancer, cervical cancer, uterine cancer, testicular cancer, rectal cancer, kidney cancer, liver cancer, stomach cancer, and lung cancer.
3. The method of claim 1 , wherein the cancer is non-small cell lung cancer, metastatic non-small cell lung cancer, colorectal cancer, metastatic colorectal cancer, pancreatic cancer, metastatic pancreatic cancer, uterine cancer, or metastatic uterine cancer.
4. The method of claim 3 , wherein the cancer is non-small cell lung cancer.
5. The method of claim 3 , wherein the cancer is colorectal cancer.
6. The method of claim 1 , wherein the compound that inhibits FAK, SRC, and JAK2 is administered at the same time as, before, or after the at least one agent that inhibits KRAS G12C.
7. The method of claim 1 , wherein IL-6 secretion from the cancer is decreased.
8. The method of claim 1 , wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C or a small molecule inhibitor of KRAS G12C.
9. The method of claim 1 , wherein the at least one agent that inhibits KRAS G12C is a biological agent that inhibits KRAS G12C.
10. The method of claim 9 , wherein the biological agent that inhibits KRAS G12C is an antibody, an antibody fragment, a peptide, an oligonucleotide, a ribonucleic acid, or an siRNA.
11. The method of claim 1 , wherein the at least one agent that inhibits KRAS G12C is a small molecule inhibitor of KRAS G12C.
12. The method of claim 1 , wherein the at least one agent that inhibits KRAS G12C is AMG-510, MRTX849, JNJ-74699157, ARS-1620, MRTX1257, RM-007, or ADT-007.
13. The method of claim 12 , wherein the at least one agent that inhibits KRAS G12C is AMG-510, or a pharmaceutically acceptable salt thereof.
14. The method of claim 12 , wherein the at least one agent that inhibits KRAS G12C is MRTX849, or a pharmaceutically acceptable salt thereof.
15. The method of claim 1 , wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 100 mg to about 300 mg, or about 160 mg; and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg to about 3 g, or about 1 mg to about 50 mg, or about 50 to about 250 mg, or about 150 to about 500 mg, or about 150 to about 250 mg, or about 250 mg to about 1 g, or about 100 mg to about 2 g, or about 500 mg to about 2 g, or about 500 mg to about 1 g, or about 800 mg to about 1.5 g, or at least 800 mg, or at least 600 mg, or about 960 mg, or about 600 mg.
16. The method of claim 1 , wherein the compound that inhibits FAK, SRC and JAK2 is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg and the at least one agent that inhibits KRAS G12C is administered at a dose of about 0.1 mg/kg to about 1 g/kg, or about 0.5 mg/kg to about 50 mg/kg, or about 0.5 mg/kg to about 25 mg/kg, or about 1.0 mg/kg to about 10 mg/kg, or about 1.0 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 5 mg/kg, or about 0.1 mg/kg to about 1 mg/kg, or about 0.1 mg/kg to about 0.6 mg/kg, or about 1.25 mg/kg to about 3.75 mg/kg, or about 1.0 mg/kg, about 2.0 mg/kg, or about 3.0 mg/kg, or about 4.0 mg/kg.
17. The method of claim 1 , wherein the host animal is a human patient in need of such treatment who has not received a prior treatment.
18. The method of claim 1 , wherein the host animal is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies.
19. The method of claim 1 , wherein the host animal is a human patient in need of such treatment who has received at least one prior treatment of one or more chemotherapeutic agents or immunotherapies, and developed an acquired resistance to the treatment, and/or developed bypass resistance to the treatment, and/or developed bypass resistance to the treatment regulated by FAK, SRC or JAK2.
20. A pharmaceutical composition comprising a therapeutically effective amount of a compound that inhibits FAK, SRC, and JAK2, in combination with a therapeutically effective amount of at least one agent that inhibits KRAS G12C, and a pharmaceutically acceptable excipient, wherein the compound is
or a pharmaceutically acceptable salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/138,644 US20240033266A1 (en) | 2019-11-27 | 2023-04-24 | Combination therapy involving diaryl macrocyclic compounds |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962941026P | 2019-11-27 | 2019-11-27 | |
US202062981822P | 2020-02-26 | 2020-02-26 | |
US202063005681P | 2020-04-06 | 2020-04-06 | |
US17/104,752 US11654145B2 (en) | 2019-11-27 | 2020-11-25 | Combination therapy involving diaryl macrocyclic compounds |
US18/138,644 US20240033266A1 (en) | 2019-11-27 | 2023-04-24 | Combination therapy involving diaryl macrocyclic compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/104,752 Continuation US11654145B2 (en) | 2019-11-27 | 2020-11-25 | Combination therapy involving diaryl macrocyclic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240033266A1 true US20240033266A1 (en) | 2024-02-01 |
Family
ID=76129920
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/104,752 Active 2041-04-03 US11654145B2 (en) | 2019-11-27 | 2020-11-25 | Combination therapy involving diaryl macrocyclic compounds |
US18/138,644 Pending US20240033266A1 (en) | 2019-11-27 | 2023-04-24 | Combination therapy involving diaryl macrocyclic compounds |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/104,752 Active 2041-04-03 US11654145B2 (en) | 2019-11-27 | 2020-11-25 | Combination therapy involving diaryl macrocyclic compounds |
Country Status (12)
Country | Link |
---|---|
US (2) | US11654145B2 (en) |
EP (1) | EP4065125A4 (en) |
JP (1) | JP2023505056A (en) |
KR (1) | KR20220133866A (en) |
CN (1) | CN114901286A (en) |
AU (1) | AU2020391222A1 (en) |
BR (1) | BR112022010278A2 (en) |
CA (1) | CA3162632A1 (en) |
IL (1) | IL293206A (en) |
MX (1) | MX2022006500A (en) |
TW (1) | TW202133855A (en) |
WO (1) | WO2021108682A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022009347A (en) * | 2020-01-31 | 2022-12-15 | Verastem Inc | Combination therapy for treating abnormal cell growth. |
KR20230157379A (en) * | 2021-03-17 | 2023-11-16 | 암젠 인크 | Sotorasib Dosing Regimen |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2779843A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
CA2936079C (en) | 2014-01-24 | 2022-07-19 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
JO3556B1 (en) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
CA2989327A1 (en) * | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
AU2016289454B2 (en) * | 2015-07-06 | 2020-07-09 | Turning Point Therapeutics, Inc. | Diaryl macrocycle polymorph |
BR112018008357A2 (en) * | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | dot mutations in trk inhibitor resistant cancer and related methods |
TWI808958B (en) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | Combination therapy involving diaryl macrocyclic compounds |
US20190134056A1 (en) * | 2017-03-10 | 2019-05-09 | The Trustees Of The Stevens Institute Of Technolog | K-ras mutations and antagonists |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
AU2018369759B2 (en) | 2017-11-15 | 2022-11-24 | Array Biopharma Inc. | KRas G12C inhibitors |
WO2019143977A1 (en) * | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
JP2022500381A (en) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス, インコーポレイテッド | Combination therapy |
CN110256421A (en) * | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | KRAS-G12C inhibitor |
AU2020391220A1 (en) * | 2019-11-27 | 2022-06-30 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
-
2020
- 2020-11-25 EP EP20894516.2A patent/EP4065125A4/en active Pending
- 2020-11-25 US US17/104,752 patent/US11654145B2/en active Active
- 2020-11-25 CA CA3162632A patent/CA3162632A1/en active Pending
- 2020-11-25 WO PCT/US2020/062390 patent/WO2021108682A1/en unknown
- 2020-11-25 KR KR1020227021852A patent/KR20220133866A/en unknown
- 2020-11-25 BR BR112022010278A patent/BR112022010278A2/en unknown
- 2020-11-25 MX MX2022006500A patent/MX2022006500A/en unknown
- 2020-11-25 TW TW109141454A patent/TW202133855A/en unknown
- 2020-11-25 CN CN202080089330.6A patent/CN114901286A/en active Pending
- 2020-11-25 JP JP2022531006A patent/JP2023505056A/en active Pending
- 2020-11-25 IL IL293206A patent/IL293206A/en unknown
- 2020-11-25 AU AU2020391222A patent/AU2020391222A1/en active Pending
-
2023
- 2023-04-24 US US18/138,644 patent/US20240033266A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4065125A4 (en) | 2024-01-03 |
BR112022010278A2 (en) | 2022-10-04 |
AU2020391222A1 (en) | 2022-06-30 |
IL293206A (en) | 2022-07-01 |
MX2022006500A (en) | 2022-07-04 |
US11654145B2 (en) | 2023-05-23 |
CA3162632A1 (en) | 2021-06-03 |
EP4065125A1 (en) | 2022-10-05 |
US20210220364A1 (en) | 2021-07-22 |
CN114901286A (en) | 2022-08-12 |
WO2021108682A1 (en) | 2021-06-03 |
KR20220133866A (en) | 2022-10-05 |
TW202133855A (en) | 2021-09-16 |
JP2023505056A (en) | 2023-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11291667B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
US11452725B2 (en) | Chiral diaryl macrocycles and uses thereof | |
US20240033266A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
US11666574B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
US11400091B2 (en) | AXL kinase inhibitors and use of the same | |
CN111643504A (en) | Combinations of AKT inhibitor compounds and chemotherapeutic agents and methods of use | |
US11851445B2 (en) | Compounds and uses thereof | |
BR112020019814A2 (en) | TREATMENT OF SUPURATIVE HYDRADENITIS USING JAK INHIBITORS | |
EP3752161A1 (en) | Methods for treating fibrosis | |
RU2784853C2 (en) | Combination therapy using diaryl macrocyclic compounds | |
CN113395968B (en) | Combination of FAK inhibitor and BTK inhibitor for the treatment of diseases | |
US20230090742A1 (en) | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors | |
TW202341978A (en) | Compositions and methods for treating solid tumors | |
CN111343973A (en) | IL-8 inhibitors for the treatment of certain sarcomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |